Docket No. CYTH-023/001WO 335739-2181 METHODS OF USING A (THIAZOLYL) BENZENESULFONAMIDE DERIVATIVE RELATED APPLICATIONS [001] This application claims priority to, and the benefit of, U.S. Provisional Patent Application No.63/417,666, filed on October 19, 2022; U.S. Provisional Patent Application No.63/501,370, filed on May 10, 2023; and U.S. Provisional Patent Application No. 63/579,245, filed on August 28, 2023; the entire contents of each of which are hereby incorporated by reference in their entirety. BACKGROUND [002] Monocarboxylate transporters (MCTs) mediate influx and efflux of monocarboxylates such as lactate, pyruvate, ketone bodies (acetoacetate and beta- hydroxybutyrate) across cell membranes. Monocarboxylates play a central role in cellular metabolism and metabolic communications among tissues. MCT family contains 14 members (e.g., MCT1, MCT2, MCT3, and MCT4 perform the function of transporting lactate, pyruvate, and ketone bodies). [003] Cancer cells often utilize glycolysis rather than, or in addition to, oxidative phosphorylation to generate energy by metabolizing glucose into lactate, and are thus referred to as glycolytic tumors. In order to avoid lactate-induced cytotoxicity, glycolytic cancer cells upregulate the expression of MCTs. Thus, there is a need to provide compounds as MCT modulators and use of these compounds as therapeutic agents, along or in combination with other therapeutics. BRIEF DESCRIPTION OF THE FIGURES [004] FIG.1 depicts patient enrollment and disposition. [005] FIGs.2A (Compound A+capecitabine) and 2B (Compound A+gemcitabine) depict the summary of treatment-emergent adverse events occurring in ^ 10 % of patients by relatedness. [006] FIGs.3A and 3B depict the Compound A pharmacokinetic profiles across combination dose levels. FIG.3A depicts the Compound A plasma PK profiles in combination with capecitabine on C2D1. FIG.3B depicts Compound A plasma PK profiles in combination with gemcitabine on C1D22. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [007] FIG.4 depicts a Swimmer’s plot of duration of treatment and response when using the combination of Compound A and capecitabine. [008] FIG.5 depicts a waterfall plot of best percentage change in tumor size when using the combination of Compound A and capecitabine. [009] FIG.6 depicts PR in ovarian cancer treated with Compound A (300 mg) and capecitabine. [010] FIG.7 depicts a Swimmer’s plot of duration of treatment and response when using the combination of Compound A and gemcitabine. [011] FIG.8 depicts a waterfall plot of best percentage change in tumor size when using the combination of Compound A and gemcitabine. [012] FIG.9 depicts enhanced cytotoxic effect of Compound A when used in combination with metformin. [013] FIG.10 depicts the additional synthetic lethal hits generated from SU8686 Compound A sensitivity CRISPR screen. [014] FIG.11 depicts the gene sets enriched from hits in SU8686 screen. [015] FIG.12 depicts Compound A combination data with 5-FU or gemcitabine. [016] FIG.13 depicts Compound A combination data with 5-FU or gemcitabine in 24 cell line panel. [017] FIG.14A depicts the % viable (Bliss Model Predicted Additive) in vitro synergy between Compound A and 5-FU in Panc 04.03 pancreatic cancer cell line. [018] FIG.14B depicts the % viable (Experimental) in vitro synergy between Compound A and 5-FU in Panc 04.03 pancreatic cancer cell line. [019] FIG.14C depicts the Synergy Score of the in vitro synergy between Compound A and 5-FU. [020] FIG.14D depicts that Compound A synergizes with 5-fluorouracil in Panc0403 pancreatic cancer cell model. [021] FIG.15 depicts the combination benefit of Compound A and capecitabine in pancreatic model in terms of tumor growth. [022] FIG.16 depicts the combination benefit of Compound A and capecitabine in pancreatic model in terms of body weight. [023] FIG.17 depicts treatment-emergent adverse events occurring in ^ 10 % of patients by relatedness. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [024] FIG.18 depicts Compound A pharmacokinetic profiles across combination dose levels. [025] FIG.19 depicts waterfall plot of best percentage change in target lesion size. [026] FIG.20 depicts sum of target lesion sizes by RECIST. [027] FIG.21 depicts Kaplan-Meier Estimate of progression-free survival (days). [028] FIG.22 depicts Swimmer’s Plot of duration of treatment and response. [029] FIG.23 depicts confirmed PR in ovarian cancer with Compound A (400 mg) + capecitabine in patient 230, a 72-year-old platinum refractory female with high grade serous ovarian cancer previously treated with carboplatin/paclitaxel, niraparib, carboplatin/liposomal doxorubicin, gemcitabine, and experimental therapy. She was treated with Compound A, 400 mg QD + capecitabine and experienced a PR after 2 cycles, with 63% reduction in the sum of target lesion longest diameters, confirmed after 4 cycles, with 78% tumor reduction. She continues treatment in Cycle 5. [030] FIG.24 depicts confirmed PR in ovarian cancer with Compound A (300 mg) + capecitabine in patient 184, a 67-year-old platinum refractory female with high grade serous ovarian cancer previously treated with 11 lines of therapy, including carboplatin, paclitaxel, gemcitabine, bevacizumab, topotecan, liposomal doxorubicin, pembrolizumab, and cyclophosphamide. Her most recent two therapies were nab-paclitaxel/bevacizumab and pemetrexed with best response of PD. She was treated with Compound A, 300 mg QD and experienced a PR after 7 cycles, confirmed at 9 cycles, shown (study day 167), with – 35% reduction in the sum of target lesion longest diameters. She discontinued therapy on day 300 for PD. DESCRIPTION [031] The present disclosure relates to using Compound A: (Compound A), or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent, for the treatment and/or prevention of a disease or disorder with implicated MCT activity. [032] The present disclosure relates to using Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 capecitabine, gemcitabine, metformin, IACS-010759 and fluorouracil (5-FU), for the treatment and/or prevention of a disease or disorder with implicated MCT activity. [033] The present disclosure also relates to a method of treating and/or preventing a disease or disorder with implicated MCT activity, comprising administering Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU. [034] The present disclosure further relates to use of Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU, for the preparation of a medicament for the treatment and/or prevention of a disease or disorder with implicated MCT activity. [035] The present disclosure further relates to Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU, for use in treating and/or preventing a disease or disorder with implicated MCT activity. [036] The present disclosure relates to using Compound A or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU, for the treatment and/or prevention of cancer. [037] The present disclosure also relates to a method of treating and/or preventing cancer, comprising administering Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU. [038] The present disclosure further relates to use of Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU, for the preparation of a medicament for the treatment and/or prevention of cancer. [039] The present disclosure further relates to Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU, for use in treating and/or preventing cancer. [040] The present disclosure relates to using Compound A or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU, for the treatment and/or prevention of solid tumors. [041] The present disclosure also relates to a method of treating and/or preventing solid tumors, comprising administering Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU. [042] The present disclosure further relates to use of Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU, for the preparation of a medicament for the treatment and/or prevention of solid tumors. [043] The present disclosure further relates to Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and 5-FU, for use in treating and/or preventing solid tumors. [044] In some embodiments, the second therapeutic agent is an inhibitor of oxidative phosphorylation. [045] In some embodiments, the second therapeutic agent is capecitabine, 5-FU or gemcitabine. [046] In some embodiments, the second therapeutic agent is capecitabine or 5-FU. [047] In some embodiments, the second therapeutic agent is capecitabine or gemcitabine. [048] In some embodiments, the second therapeutic agent is capecitabine. [049] In some embodiments, the second therapeutic agent is gemcitabine. [050] In some embodiments, the second therapeutic agent is metformin. [051] In some embodiments, the second therapeutic agent is IACS-010759. [052] In some embodiments, the second therapeutic agent is 5-FU. [053] In some embodiments, the cancer is a solid tumor. [054] In some embodiments, the solid tumor is ovarian cancer or pancreatic cancer. Definitions [055] The term “pharmaceutically acceptable salt” refers to a pharmaceutical salt that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, and allergic response, and is commensurate with a reasonable benefit/risk ratio. Pharmaceutically-acceptable salts are well 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 known in the art. For example, S. M. Berge et al. describes pharmacologically acceptable salts in J. Pharm. Sci., 1977, 66, 1–19. [056] As used herein, the term “subject” includes human and non-human animals, as well as cell lines, cell cultures, tissues, and organs. In some embodiments, the subject is a mammal. The mammal can be e.g., a human or appropriate non-human mammal, such as primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep or a pig. The subject can also be a bird or fowl. In some embodiments, the subject is a human. [057] As used herein, the term “subject in need thereof” refers to a subject having a disease or having an increased risk of developing the disease. A subject in need thereof can be one who has been previously diagnosed or identified as having a disease or disorder disclosed herein. A subject in need thereof can also be one who is suffering from a disease or disorder disclosed herein. Alternatively, a subject in need thereof can be one who has an increased risk of developing such disease or disorder relative to the population at large (i.e., a subject who is predisposed to developing such disorder relative to the population at large). A subject in need thereof can have a refractory or resistant a disease or disorder disclosed herein (i.e., a disease or disorder disclosed herein that does not respond or has not yet responded to treatment). The subject may be resistant at start of treatment or may become resistant during treatment. In some embodiments, the subject in need thereof received and failed all known effective therapies for a disease or disorder disclosed herein. In some embodiments, the subject in need thereof received at least one prior therapy. [058] As used herein, the term “treating”, “treatment”, or “treat” describes the management and care of a subject for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder. The term “treat” can also include treatment of a cell in vitro or an animal model. [059] As used herein, the term “preventing,” “prevention”, “prevent,” or “protecting against” describes reducing or eliminating the onset of the symptoms or complications of such disease, condition or disorder. [060] As used herein, the term “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use. A “pharmaceutically acceptable 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 excipient” as used in the specification and claims includes both one and more than one such excipient. [061] As used herein, the term “therapeutically effective amount”, refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend upon the subject’s body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician. [062] As used herein, the term “pharmaceutical composition” is a formulation containing the compounds of the present disclosure in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler or a vial. The quantity of active ingredient (e.g., a formulation of the disclosed compound or salt, hydrate, solvate or isomer thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved. One skilled in the art will appreciate that it is sometimes necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalational, buccal, sublingual, intrapleural, intrathecal, intranasal, and the like. Dosage forms for the topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required. [063] As used herein, the term “pharmaceutically acceptable” refers to those compounds, anions, cations, materials, compositions, carriers, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [064] As used herein, the term “second therapeutic agent” or “second agent” is capecitabine, gemcitabine, metformin, IACS-010759 and/or 5-FU. [065] It is to be understood that a compound or pharmaceutical composition of the disclosure can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment. For example, a compound of the disclosure may be injected into the blood stream or body cavities or taken orally or applied through the skin with patches. The dose chosen should be sufficient to constitute effective treatment but not so high as to cause unacceptable side effects. The state of the disease condition (e.g., a disease or disorder disclosed herein) and the health of the patient should preferably be closely monitored during and for a reasonable period after treatment. [066] The terms "co-administration" or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time. [067] Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. [068] The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc. [069] As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” [070] The term “about” and the like, as used herein, in association with numeric values or ranges, reflects the fact that there is a certain level of variation that is recognized and tolerated in the art due to practical and/or theoretical limitations. For example, minor variation is tolerated due to inherent variances in the manner in which certain devices operate and/or measurements are taken. In accordance with the above, the phrase “about” is normally used to encompass values within the standard deviation or standard error. [071] In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03. [072] As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from anyone or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a nonlimiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc. [073] It should also be understood that, in certain methods described herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited unless the context indicates otherwise. [074] All percentages and ratios used herein, unless otherwise indicated, are by weight. Other features and advantages of the present disclosure are apparent from the different examples. The provided examples illustrate different components and methodology useful in practicing the present disclosure. The examples do not limit the claimed disclosure. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present disclosure. Combination of Compound A with a Second Therapeutic Agent [075] Disclosed herein, in certain embodiments, are combinations comprising Compound A and a second therapeutic agent selected from capecitabine and gemcitabine. [076] Further disclosed herein, in certain embodiments, are pharmaceutical combinations comprising Compound A and a second therapeutic agent selected from capecitabine and gemcitabine. [077] In some embodiments, Compound A and the second therapeutic agent selected from capecitabine and gemcitabine are co-administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially. [078] In some embodiments, the co-administration of Compound A and the second therapeutic agent selected from capecitabine and gemcitabine increases the bioavailability of Compound A. In some embodiments, the co-administration of Compound A and the second therapeutic agent selected from capecitabine and gemcitabine increases the C _max of Compound A. In some embodiments, the co-administration of Compound A and the second therapeutic agent selected from capecitabine and gemcitabine increases the AUC of Compound A. In some embodiments, the co-administration of Compound A and the second therapeutic agent selected from capecitabine and gemcitabine increases the T1/2 of Compound A. [079] Compositions or therapies disclosed herein may be administered individually to a patient or may be administered in combination (e.g. simultaneously, sequentially or separately). In some embodiments, Compound A is administered in advance of the second 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 therapeutic agent. In some embodiments, Compound A is administered in advance of the second therapeutic agent and the second therapeutic agent is capecitabine. In some embodiments, Compound A is administered in advance of the second therapeutic agent and the second therapeutic agent is gemcitabine. In some embodiments, the second therapeutic agent selected from capecitabine and gemcitabine is administered before Compound A. In some embodiments, the second therapeutic agent selected from capecitabine and gemcitabine is capecitabine and is administered in advance of Compound A. In some embodiments, the second therapeutic agent is gemcitabine and is administered in advance of Compound A. [080] In some embodiments, Compound A and the second therapeutic agent selected from capecitabine and gemcitabine are administered in temporal proximity (e.g., Compound A and the second therapeutic agent selected from capecitabine and gemcitabine can be initially administered simultaneously). Accordingly, the present disclosure provides a method of treating or preventing cancer comprising administering Compound A and a second therapeutic agent selected from capecitabine and gemcitabine in temporal proximity. In some embodiments, “temporal proximity” means that administration of one therapeutic agent occurs within a time period before or after the administration of another therapeutic agent, such that the therapeutic effect of the one therapeutic agent overlaps with the therapeutic effect of the another therapeutic agent. In some embodiments, the therapeutic effect of the one therapeutic agent completely overlaps with the therapeutic effect of the other therapeutic agent. [081] In some embodiments, “temporal proximity” means that administration of one therapeutic agent occurs within a time period before or after the administration of another therapeutic agent, such that there is a synergistic effect between the one therapeutic agent and the another therapeutic agent. “Temporal proximity” may vary according to various factors, including but not limited to, the age, gender, weight, genetic background, medical condition, disease history, and treatment history of the subject to which the therapeutic agents are to be administered; the disease or condition to be treated or ameliorated; the therapeutic outcome to be achieved; the dosage, dosing frequency, and dosing duration of the therapeutic agents; the pharmacokinetics and pharmacodynamics of the therapeutic agents; and the route(s) through which the therapeutic agents are administered. In some embodiments, “temporal proximity” means within 15 minutes, within 30 minutes, within an hour, within two hours, within four hours, within six hours, within eight hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 within a week, within 2 weeks, within 3 weeks, within 4 weeks, with 6 weeks, or within 8 weeks. In some embodiments, multiple administration of one therapeutic agent can occur in temporal proximity to a single administration of another therapeutic agent. In some embodiments, temporal proximity may change during a treatment cycle or within a dosing regimen. [082] “Combination therapy” is intended to embrace administration of the therapeutic agents disclosed herein in a sequential or simultaneous manner, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents concurrently, or in a substantially simultaneous manner. Simultaneous administration can be accomplished, for example, by administering to the subject a single capsule having a fixed or variable ratio of each therapeutic agent or in multiple, single capsules for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be affected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally, or all therapeutic agents may be administered by intravenous injection. The sequence in which the therapeutic agents are administered can vary. Therapeutic agents may also be administered in alternation. [083] In some embodiments, the disclosure provides a synergistic combination of Compound A and the second therapeutic agent, wherein Compound A and the second therapeutic agent selected from capecitabine and gemcitabine come into contact with each other in the human body (e.g., only in the human body). In some embodiments, the disclosure provides a method of preparing a combination therapy by bringing Compound A and the second therapeutic agent selected from capecitabine and gemcitabine into contact with each other at a locus. In some embodiments, the method of preparing a combination therapy by bringing Compound A and the second therapeutic agent selected from capecitabine and gemcitabine into contact with each other at a locus occurs in the human body (e.g., only in the human body). 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [084] In some embodiments, Compound A and the second therapeutic agent selected from capecitabine and gemcitabine are co-administration concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially. [085] In some embodiments, Compound A and the second therapeutic agent selected from capecitabine and gemcitabine are co-administered in separate dosage forms. In some embodiments, Compound A and the second therapeutic agent selected from capecitabine and gemcitabine are co-administered in combined dosage forms. [086] In some embodiments, the co-administration of Compound A and the second therapeutic agent selected from capecitabine and gemcitabine increases the bioavailability of Compound A. In some embodiments, the co-administration of Compound A and the second therapeutic agent selected from capecitabine and gemcitabine increases the Cmax of Compound A. In some embodiments, the co-administration of Compound A and the second therapeutic agent selected from capecitabine and gemcitabine increases the AUC of Compound A. In some embodiments, the co-administration of Compound A and the second therapeutic agent selected from capecitabine and gemcitabine increases the T1/2 of Compound A. Dosing and Treatment Regimens [087] In some embodiments, described herein is a method of treating and/or preventing a disease or disorder with implicated MCT activity, a cancer, or a solid tumor, the method comprising administering a therapeutically effective dose of Compound A, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second therapeutic agent selected from capecitabine and gemcitabine to a subject in need thereof. [088] In some embodiments, described herein is a use of Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine and gemcitabine, for the preparation of a medicament for the treatment and/or prevention of a disease or disorder with implicated MCT activity, a cancer, or a solid tumor in a subject in need thereof. [089] In some embodiments, described herein is using Compound A or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent selected from capecitabine and gemcitabine, for use in treating and/or preventing a disease or disorder with implicated MCT activity, a cancer, or a solid tumor in a subject in need thereof. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [090] In some embodiments, described herein is a combination composition (e.g., a composition comprising a combination of Compound A, or a pharmaceutically acceptable salt thereof, and a second therapeutic agent selected from capecitabine and gemcitabine) for use in treating and/or preventing a disease or disorder with implicated MCT activity, a cancer, or a solid tumor in a subject in need thereof. [091] In some embodiments, described herein is a use of a combination composition (e.g., a composition comprising a combination of Compound A, or a pharmaceutically acceptable salt thereof, and a second therapeutic agent selected from capecitabine and gemcitabine) for the treatment and/or prevention of a disease or disorder with implicated MCT activity, a cancer, or a solid tumor in a subject in need thereof. [092] In some embodiments, described herein is a use of a combination composition (e.g., a composition comprising a combination of Compound A, or a pharmaceutically acceptable salt thereof, and a second therapeutic agent selected from capecitabine and gemcitabine) in the manufacture of a medicament for the treatment and/or prevention of solid tumor in a subject in need thereof. [093] In some embodiments, the subject is a mammal. [094] In some embodiments, the subject is a human. [095] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg to about 800 mg. [096] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg to about 700 mg. [097] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg to about 600 mg. [098] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg to about 500 mg. [099] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg to about 400 mg. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0100] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg to about 300 mg. [0101] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg to about 200 mg. [0102] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg to about 800 mg. [0103] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg to about 700 mg. [0104] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg to about 600 mg. [0105] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg to about 500 mg. [0106] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg to about 400 mg. [0107] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg to about 300 mg. [0108] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg to about 800 mg. [0109] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg to about 700 mg. [0110] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg to about 600 mg. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0111] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg to about 500 mg. [0112] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg to about 400 mg. [0113] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg to about 800 mg. [0114] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg to about 700 mg. [0115] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg to about 600 mg. [0116] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg to about 500 mg. [0117] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 500 mg to about 800 mg. [0118] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 500 mg to about 700 mg. [0119] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 500 mg to about 600 mg. [0120] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 600 mg to about 800 mg. [0121] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 600 mg to about 700 mg. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0122] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 700 mg to about 800 mg. [0123] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, or about 800 mg. [0124] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 100 mg. [0125] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 200 mg. [0126] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 300 mg. [0127] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 400 mg. [0128] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 500 mg. [0129] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 600 mg. [0130] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 700 mg. [0131] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 800 mg. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0132] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 1000 mg/day. [0133] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 1000 mg/day. [0134] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 1000 mg/day. [0135] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 1000 mg/day. [0136] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 250 mg/day to about 1000 mg/day. [0137] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg/day to about 1000 mg/day. [0138] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 350 mg/day to about 1000 mg/day. [0139] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg/day to about 1000 mg/day. [0140] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 450 mg/day to about 1000 mg/day. [0141] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 500 mg/day to about 1000 mg/day. [0142] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 550 mg/day to about 1000 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0143] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 600 mg/day to about 1000 mg/day. [0144] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 700 mg/day to about 1000 mg/day. [0145] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 800 mg/day to about 1000 mg/day. [0146] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 900 mg/day to about 1000 mg/day. [0147] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 900 mg/day. [0148] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 900 mg/day. [0149] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 900 mg/day. [0150] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 900 mg/day. [0151] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 250 mg/day to about 900 mg/day. [0152] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg/day to about 900 mg/day. [0153] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 350 mg/day to about 900 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0154] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg/day to about 900 mg/day. [0155] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 450 mg/day to about 900 mg/day. [0156] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 500 mg/day to about 900 mg/day. [0157] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 550 mg/day to about 900 mg/day. [0158] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 600 mg/day to about 900 mg/day. [0159] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 700 mg/day to about 900 mg/day. [0160] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 800 mg/day to about 900 mg/day. [0161] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 800 mg/day. [0162] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 800 mg/day. [0163] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 800 mg/day. [0164] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 800 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0165] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 250 mg/day to about 800 mg/day. [0166] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg/day to about 800 mg/day. [0167] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 350 mg/day to about 800 mg/day. [0168] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg/day to about 800 mg/day. [0169] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 450 mg/day to about 800 mg/day. [0170] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 500 mg/day to about 800 mg/day. [0171] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 550 mg/day to about 800 mg/day. [0172] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 600 mg/day to about 800 mg/day. [0173] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 700 mg/day to about 800 mg/day. [0174] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 700 mg/day. [0175] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 700 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0176] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 700 mg/day. [0177] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 700 mg/day. [0178] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 250 mg/day to about 700 mg/day. [0179] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg/day to about 700 mg/day. [0180] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 350 mg/day to about 700 mg/day. [0181] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg/day to about 700 mg/day. [0182] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 450 mg/day to about 700 mg/day. [0183] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 500 mg/day to about 700 mg/day. [0184] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 550 mg/day to about 700 mg/day. [0185] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 600 mg/day to about 700 mg/day. [0186] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 600 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0187] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 600 mg/day. [0188] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 600 mg/day. [0189] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 600 mg/day. [0190] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 250 mg/day to about 600 mg/day. [0191] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg/day to about 600 mg/day. [0192] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 350 mg/day to about 600 mg/day. [0193] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg/day to about 600 mg/day. [0194] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 450 mg/day to about 600 mg/day. [0195] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 500 mg/day to about 600 mg/day. [0196] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 550 mg/day to about 600 mg/day. [0197] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 500 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0198] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 500 mg/day. [0199] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 500 mg/day. [0200] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 500 mg/day. [0201] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 250 mg/day to about 500 mg/day. [0202] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg/day to about 500 mg/day. [0203] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 350 mg/day to about 500 mg/day. [0204] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg/day to about 500 mg/day. [0205] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 450 mg/day to about 500 mg/day. [0206] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 450 mg/day. [0207] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 450 mg/day. [0208] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 450 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0209] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 450 mg/day. [0210] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 250 mg/day to about 450 mg/day. [0211] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg/day to about 450 mg/day. [0212] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 350 mg/day to about 450 mg/day. [0213] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 400 mg/day to about 450 mg/day. [0214] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 400 mg/day. [0215] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 400 mg/day. [0216] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 400 mg/day. [0217] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 400 mg/day. [0218] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 250 mg/day to about 400 mg/day. [0219] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg/day to about 400 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0220] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 350 mg/day to about 400 mg/day. [0221] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 350 mg/day. [0222] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 350 mg/day. [0223] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 350 mg/day. [0224] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 350 mg/day. [0225] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 250 mg/day to about 350 mg/day. [0226] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 300 mg/day to about 350 mg/day. [0227] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 300 mg/day. [0228] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 300 mg/day. [0229] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 300 mg/day. [0230] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 300 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0231] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 250 mg/day to about 300 mg/day. [0232] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 250 mg/day. [0233] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 250 mg/day. [0234] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 250 mg/day. [0235] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 200 mg/day to about 250 mg/day. [0236] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 200 mg/day. [0237] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 200 mg/day. [0238] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 150 mg/day to about 200 mg/day. [0239] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 150 mg/day. [0240] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 100 mg/day to about 150 mg/day. [0241] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 50 mg/day to about 100 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0242] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 50 mg/day, about 60 mg/day, about 70 mg/day, about 80 mg/day, about 90 mg/day, about 100 mg/day, about 110 mg/day, about 120 mg/day, about 130 mg/day, about 140 mg/day, about 150 mg/day, about 160 mg/day, about 170 mg/day, about 180 mg/day, about 190 mg/day, about 200 mg/day, about 210 mg/day, about 220 mg/day, about 230 mg/day, about 240 mg/day, about 250 mg/day, about 260 mg/day, about 270 mg/day, about 280 mg/day, about 290 mg/day, about 300 mg/day, about 310 mg/day, about 320 mg/day, about 330 mg/day, about 340 mg/day, about 350 mg/day, about 360 mg/day, about 370 mg/day, about 380 mg/day, about 390 mg/day, about 400 mg/day, about 410 mg/day, about 420 mg/day, about 430 mg/day, about 440 mg/day, about 450 mg/day, about 460 mg/day, about 470 mg/day, about 480 mg/day, about 490 mg/day, about 500 mg/day, about 510 mg/day, about 520 mg/day, about 530 mg/day, about 540 mg/day, about 550 mg/day, about 560 mg/day, about 570 mg/day, about 580 mg/day, about 590 mg/day, about 600 mg/day, about 610 mg/day, about 620 mg/day, about 630 mg/day, about 640 mg/day, about 650 mg/day, about 660 mg/day, about 670 mg/day, about 680 mg/day, about 690 mg/day, about 700 mg/day, about 710 mg/day, about 720 mg/day, about 730 mg/day, about 740 mg/day, about 750 mg/day, about 760 mg/day, about 770 mg/day, about 780 mg/day, about 790 mg/day, about 800 mg/day, about 810 mg/day, about 820 mg/day, about 830 mg/day, about 840 mg/day, about 850 mg/day, about 860 mg/day, about 870 mg/day, about 880 mg/day, about 890 mg/day, about 900 mg/day, about 910 mg/day, about 920 mg/day, about 930 mg/day, about 940 mg/day, about 950 mg/day, about 960 mg/day, about 970 mg/day, about 980 mg/day, about 990 mg/day, or about 1000 mg/day. [0243] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 50 mg/day. [0244] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 60 mg/day. [0245] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 70 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0246] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 80 mg/day. [0247] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 90 mg/day. [0248] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 100 mg/day. [0249] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 110 mg/day. [0250] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 120 mg/day. [0251] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 130 mg/day. [0252] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 140 mg/day. [0253] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 150 mg/day. [0254] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 160 mg/day. [0255] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 170 mg/day. [0256] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 180 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0257] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 190 mg/day. [0258] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 200 mg/day. [0259] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 210 mg/day. [0260] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 220 mg/day. [0261] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 230 mg/day. [0262] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 240 mg/day. [0263] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 250 mg/day. [0264] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 260 mg/day. [0265] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 270 mg/day. [0266] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 280 mg/day. [0267] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 290 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0268] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 300 mg/day. [0269] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 310 mg/day. [0270] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 320 mg/day. [0271] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 330 mg/day. [0272] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 340 mg/day. [0273] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 350 mg/day. [0274] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 360 mg/day. [0275] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 370 mg/day. [0276] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 380 mg/day. [0277] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 390 mg/day. [0278] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 400 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0279] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 410 mg/day. [0280] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 420 mg/day. [0281] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 430 mg/day. [0282] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 440 mg/day. [0283] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 450 mg/day. [0284] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 460 mg/day. [0285] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 470 mg/day. [0286] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 480 mg/day. [0287] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 490 mg/day. [0288] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 500 mg/day. [0289] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 510 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0290] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 520 mg/day. [0291] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 530 mg/day. [0292] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 540 mg/day. [0293] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 550 mg/day. [0294] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 560 mg/day. [0295] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 570 mg/day. [0296] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 580 mg/day. [0297] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 590 mg/day. [0298] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 600 mg/day. [0299] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 610 mg/day. [0300] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 620 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0301] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 630 mg/day. [0302] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 640 mg/day. [0303] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 650 mg/day. [0304] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 660 mg/day. [0305] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 670 mg/day. [0306] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 680 mg/day. [0307] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 690 mg/day. [0308] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 700 mg/day. [0309] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 710 mg/day. [0310] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 720 mg/day. [0311] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 730 mg/day. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0312] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 740 mg/day. [0313] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 750 mg/day. [0314] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 760 mg/day. [0315] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 770 mg/day. [0316] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 780 mg/day. [0317] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 790 mg/day. [0318] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 800 mg/day. [0319] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 1 mg/kg to about 50 mg/kg. [0320] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 10 mg/kg to about 40 mg/kg. [0321] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 10 mg/kg to about 30 mg/kg. [0322] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 10 mg/kg to about 20 mg/kg. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0323] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 20 mg/kg to about 50 mg/kg. [0324] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 20 mg/kg to about 40 mg/kg. [0325] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 20 mg/kg to about 30 mg/kg. [0326] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 30 mg/kg to about 50 mg/kg. [0327] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 30 mg/kg to about 40 mg/kg. [0328] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) ranges from about 40 mg/kg to about 50 mg/kg. [0329] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 1 mg/kg, about 5 mg/kg, about 9.8 mg/kg, about 10 mg/kg, about 15 mg/kg, about 16.3 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, or about 50 mg/kg. [0330] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 1 mg/kg. [0331] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 5 mg/kg. [0332] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 9.8 mg/kg. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0333] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 10 mg/kg. [0334] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 15 mg/kg. [0335] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 16.3 mg/kg. [0336] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 20 mg/kg. [0337] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 25 mg/kg. [0338] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 30 mg/kg. [0339] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 35 mg/kg. [0340] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 40 mg/kg. [0341] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 45 mg/kg. [0342] In some embodiments, the amount of Compound A that is administered in combination with a second therapeutic agent (e.g., capecitabine and gemcitabine) (e.g., human dosage) is about 50 mg/kg. [0343] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 4000 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0344] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 3500 mg/m ² . [0345] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 3000 mg/m ² . [0346] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 2500 mg/m ² . [0347] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 2000 mg/m ² . [0348] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 1500 mg/m ² . [0349] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 1000 mg/m ² . [0350] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 900 mg/m ² . [0351] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 800 mg/m ² . [0352] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 700 mg/m ² . [0353] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 600 mg/m ² . [0354] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 500 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0355] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 400 mg/m ² . [0356] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 300 mg/m ² . [0357] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 200 mg/m ² . [0358] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 4500 mg/m ² . [0359] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 4000 mg/m ² . [0360] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 3500 mg/m ² . [0361] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 3000 mg/m ² . [0362] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 2500 mg/m ² . [0363] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 2000 mg/m ² . [0364] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 1500 mg/m ² . [0365] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 1000 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0366] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 900 mg/m ² . [0367] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 800 mg/m ² . [0368] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 700 mg/m ² . [0369] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 600 mg/m ² . [0370] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 500 mg/m ² . [0371] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 400 mg/m ² . [0372] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 300 mg/m ² . [0373] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 4500 mg/m ² . [0374] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 4000 mg/m ² . [0375] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 3500 mg/m ² . [0376] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 3000 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0377] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 2500 mg/m ² . [0378] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 2000 mg/m ² . [0379] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 1500 mg/m ² . [0380] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 1000 mg/m ² . [0381] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 900 mg/m ² . [0382] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 800 mg/m ² . [0383] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 700 mg/m ² . [0384] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 600 mg/m ² . [0385] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 500 mg/m ² . [0386] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 400 mg/m ² . [0387] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 4500 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0388] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 4000 mg/m ² . [0389] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 3500 mg/m ² . [0390] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 3000 mg/m ² . [0391] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 2500 mg/m ² . [0392] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 2000 mg/m ² . [0393] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 1500 mg/m ² . [0394] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 1000 mg/m ² . [0395] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 900 mg/m ² . [0396] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 800 mg/m ² . [0397] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 700 mg/m ² . [0398] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 600 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0399] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 500 mg/m ² . [0400] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 4500 mg/m ² . [0401] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 4000 mg/m ² . [0402] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 3500 mg/m ² . [0403] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 3000 mg/m ² . [0404] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 2500 mg/m ² . [0405] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 2000 mg/m ² . [0406] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 1500 mg/m ² . [0407] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 1000 mg/m ² . [0408] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 900 mg/m ² . [0409] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 800 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0410] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 700 mg/m ² . [0411] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 600 mg/m ² . [0412] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 4500 mg/m ² . [0413] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 4000 mg/m ² . [0414] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 3500 mg/m ² . [0415] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 3000 mg/m ² . [0416] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 2500 mg/m ² . [0417] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 2000 mg/m ² . [0418] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 1500 mg/m ² . [0419] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 1000 mg/m ² . [0420] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 900 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0421] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 800 mg/m ² . [0422] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 700 mg/m ² . [0423] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 4500 mg/m ² . [0424] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 4000 mg/m ² . [0425] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 3500 mg/m ² . [0426] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 3000 mg/m ² . [0427] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 2500 mg/m ² . [0428] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 2000 mg/m ² . [0429] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 1500 mg/m ² . [0430] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 1000 mg/m ² . [0431] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 900 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0432] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 800 mg/m ² . [0433] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 4500 mg/m ² . [0434] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 4000 mg/m ² . [0435] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 3500 mg/m ² . [0436] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 3000 mg/m ² . [0437] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 2500 mg/m ² . [0438] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 2000 mg/m ² . [0439] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 1500 mg/m ² . [0440] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 1000 mg/m ² . [0441] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 900 mg/m ² . [0442] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 4500 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0443] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 4000 mg/m ² . [0444] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 3500 mg/m ² . [0445] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 3000 mg/m ² . [0446] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 2500 mg/m ² . [0447] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 2000 mg/m ² . [0448] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 1500 mg/m ² . [0449] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 1000 mg/m ² . [0450] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 4500 mg/m ² . [0451] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 4000 mg/m ² . [0452] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 3500 mg/m ² . [0453] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 3000 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0454] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 2500 mg/m ² . [0455] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 2000 mg/m ² . [0456] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 1500 mg/m ² . [0457] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1500 mg/m ² to about 4500 mg/m ² . [0458] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1500 mg/m ² to about 4000 mg/m ² . [0459] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1500 mg/m ² to about 3500 mg/m ² . [0460] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1500 mg/m ² to about 3000 mg/m ² . [0461] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1500 mg/m ² to about 2500 mg/m ² . [0462] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 1500 mg/m ² to about 2000 mg/m ² . [0463] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 2000 mg/m ² to about 4500 mg/m ² . [0464] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 2000 mg/m ² to about 4000 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0465] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 2000 mg/m ² to about 3500 mg/m ² . [0466] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 2000 mg/m ² to about 3000 mg/m ² . [0467] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 2000 mg/m ² to about 2500 mg/m ² . [0468] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 2500 mg/m ² to about 4500 mg/m ² . [0469] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 2500 mg/m ² to about 4000 mg/m ² . [0470] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 2500 mg/m ² to about 3500 mg/m ² . [0471] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 2500 mg/m ² to about 3000 mg/m ² . [0472] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 3000 mg/m ² to about 4500 mg/m ² . [0473] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 3000 mg/m ² to about 4000 mg/m ² . [0474] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 3000 mg/m ² to about 3500 mg/m ² . [0475] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 3500 mg/m ² to about 4500 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0476] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 3500 mg/m ² to about 4000 mg/m ² . [0477] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) ranges from about 4000 mg/m ² to about 4500 mg/m ² . [0478] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 100 mg/m ² , about 120 mg/m ² , about 140 mg/m ² , about 160 mg/m ² , about 180 mg/m ² , about 200 mg/m ² , about 220 mg/m ² , about 240 mg/m ² , about 260 mg/m ² , about 280 mg/m ² , about 300 mg/m ² , about 320 mg/m ² , about 340 mg/m ² , about 360 mg/m ² , about 380 mg/m ² , about 400 mg/m ² , about 420 mg/m ² , about 440 mg/m ² , about 460 mg/m ² , about 480 mg/m ² , about 500 mg/m ² , about 520 mg/m ² , about 540 mg/m ² , about 560 mg/m ² , about 580 mg/m ² , about 600 mg/m ² , about 620 mg/m ² , about 640 mg/m ² , about 660 mg/m ² , about 680 mg/m ² , about 700 mg/m ² , about 720 mg/m ² , about 740 mg/m ² , about 760 mg/m ² , about 780 mg/m ² , about 800 mg/m ² , about 820 mg/m ² , about 840 mg/m ² , about 860 mg/m ² , about 880 mg/m ² , about 900 mg/m ² , about 920 mg/m ² , about 940 mg/m ² , about 960 mg/m ² , about 980 mg/m ² , about 1000 mg/m ² , about 1020 mg/m ² , about 1040 mg/m ² , about 1060 mg/m ² , about 1080 mg/m ² , about 1100 mg/m ² , about 1120 mg/m ² , about 1140 mg/m ² , about 1160 mg/m ² , about 1180 mg/m ² , about 1200 mg/m ² , about 1220 mg/m ² , about 1240 mg/m ² , about 1260 mg/m ² , about 1280 mg/m ² , about 1300 mg/m ² , about 1320 mg/m ² , about 1340 mg/m ² , about 1360 mg/m ² , about 1380 mg/m ² , about 1400 mg/m ² , about 1420 mg/m ² , about 1440 mg/m ² , about 1460 mg/m ² , about 1480 mg/m ² , about 1500 mg/m ² , about 2000 mg/m ² , about 2200 mg/m ² , about 2400 mg/m ² , about 2600 mg/m ² , about 2800 mg/m ² , about 3000 mg/m ² , about 3200 mg/m ² , about 3400 mg/m ² , about 3600 mg/m ² , about 3800 mg/m ² , about 4000 mg/m ² , about 4200 mg/m ² , about 4400 mg/m ² , about 4600 mg/m ² , about 4800 mg/m ² , or about 5000 mg/m ² . [0479] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 100 mg/m ² . [0480] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 200 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0481] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 400 mg/m ² . [0482] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 500 mg/m ² . [0483] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 600 mg/m ² . [0484] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 700 mg/m ² . [0485] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 800 mg/m ² . [0486] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 900 mg/m ² . [0487] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 1000 mg/m ² . [0488] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 1100 mg/m ² . [0489] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 1200 mg/m ² . [0490] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 1300 mg/m ² . [0491] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 1400 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0492] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 1500 mg/m ² . [0493] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 1600 mg/m ² . [0494] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 1700 mg/m ² . [0495] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 1800 mg/m ² . [0496] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 1900 mg/m ² . [0497] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 2000 mg/m ² . [0498] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 2100 mg/m ² . [0499] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 2200 mg/m ² . [0500] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 2300 mg/m ² . [0501] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 2400 mg/m ² . [0502] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 2500 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0503] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 2600 mg/m ² . [0504] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 2700 mg/m ² . [0505] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 2800 mg/m ² . [0506] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 2900 mg/m ² . [0507] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 3000 mg/m ² . [0508] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 3100 mg/m ² . [0509] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 3200 mg/m ² . [0510] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 3300 mg/m ² . [0511] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 3400 mg/m ² . [0512] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 3500 mg/m ² . [0513] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 3600 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0514] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 3700 mg/m ² . [0515] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 3800 mg/m ² . [0516] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 3900 mg/m ² . [0517] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 4000 mg/m ² . [0518] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 4100 mg/m ² . [0519] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 4200 mg/m ² . [0520] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 4300 mg/m ² . [0521] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 4400 mg/m ² . [0522] In some embodiments, the amount of the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU that is administered in combination with Compound A (e.g., human dosage) is about 4500 mg/m ² . [0523] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 1500 mg/m ² . [0524] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 1400 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0525] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 1300 mg/m ² . [0526] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 1200 mg/m ² . [0527] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 1100 mg/m ² . [0528] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 1000 mg/m ² . [0529] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 900 mg/m ² . [0530] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 800 mg/m ² . [0531] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 700 mg/m ² . [0532] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 600 mg/m ² . [0533] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 500 mg/m ² . [0534] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 400 mg/m ² . [0535] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 300 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0536] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 100 mg/m ² to about 200 mg/m ² . [0537] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 1500 mg/m ² . [0538] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 1400 mg/m ² . [0539] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 1300 mg/m ² . [0540] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 1200 mg/m ² . [0541] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 1100 mg/m ² . [0542] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 1000 mg/m ² . [0543] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 900 mg/m ² . [0544] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 800 mg/m ² . [0545] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 700 mg/m ² . [0546] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 600 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0547] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 500 mg/m ² . [0548] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 400 mg/m ² . [0549] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 200 mg/m ² to about 300 mg/m ² . [0550] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 1500 mg/m ² . [0551] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 1400 mg/m ² . [0552] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 1300 mg/m ² . [0553] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 1200 mg/m ² . [0554] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 1100 mg/m ² . [0555] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 1000 mg/m ² . [0556] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 900 mg/m ² . [0557] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 800 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0558] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 700 mg/m ² . [0559] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 600 mg/m ² . [0560] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 500 mg/m ² . [0561] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 300 mg/m ² to about 400 mg/m ² . [0562] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 1500 mg/m ² . [0563] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 1400 mg/m ² . [0564] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 1300 mg/m ² . [0565] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 1200 mg/m ² . [0566] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 1100 mg/m ² . [0567] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 1000 mg/m ² . [0568] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 900 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0569] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 800 mg/m ² . [0570] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 700 mg/m ² . [0571] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 600 mg/m ² . [0572] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 400 mg/m ² to about 500 mg/m ² . [0573] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 1500 mg/m ² . [0574] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 1400 mg/m ² . [0575] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 1300 mg/m ² . [0576] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 1200 mg/m ² . [0577] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 1100 mg/m ² . [0578] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 1000 mg/m ² . [0579] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 900 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0580] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 800 mg/m ² . [0581] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 700 mg/m ² . [0582] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 500 mg/m ² to about 600 mg/m ² . [0583] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 1500 mg/m ² . [0584] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 1400 mg/m ² . [0585] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 1300 mg/m ² . [0586] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 1200 mg/m ² . [0587] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 1100 mg/m ² . [0588] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 1000 mg/m ² . [0589] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 900 mg/m ² . [0590] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 800 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0591] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 600 mg/m ² to about 700 mg/m ² . [0592] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 1500 mg/m ² . [0593] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 1400 mg/m ² . [0594] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 1300 mg/m ² . [0595] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 1200 mg/m ² . [0596] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 1100 mg/m ² . [0597] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 1000 mg/m ² . [0598] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 900 mg/m ² . [0599] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 700 mg/m ² to about 800 mg/m ² . [0600] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 1500 mg/m ² . [0601] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 1400 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0602] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 1300 mg/m ² . [0603] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 1200 mg/m ² . [0604] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 1100 mg/m ² . [0605] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 1000 mg/m ² . [0606] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 800 mg/m ² to about 900 mg/m ² . [0607] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 1500 mg/m ² . [0608] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 1400 mg/m ² . [0609] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 1300 mg/m ² . [0610] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 1200 mg/m ² . [0611] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 1100 mg/m ² . [0612] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 900 mg/m ² to about 1000 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0613] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 1500 mg/m ² . [0614] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 1400 mg/m ² . [0615] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 1300 mg/m ² . [0616] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 1200 mg/m ² . [0617] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1000 mg/m ² to about 1100 mg/m ² . [0618] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1100 mg/m ² to about 1500 mg/m ² . [0619] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1100 mg/m ² to about 1400 mg/m ² . [0620] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1100 mg/m ² to about 1300 mg/m ² . [0621] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1100 mg/m ² to about 1200 mg/m ² . [0622] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1200 mg/m ² to about 1500 mg/m ² . [0623] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1200 mg/m ² to about 1300 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0624] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1200 mg/m ² to about 1400 mg/m ² . [0625] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1300 mg/m ² to about 1500 mg/m ² . [0626] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1300 mg/m ² to about 1400 mg/m ² . [0627] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) ranges from about 1400 mg/m ² to about 1500 mg/m ² . [0628] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 100 mg/m ² , about 120 mg/m ² , about 140 mg/m ² , about 160 mg/m ² , about 180 mg/m ² , about 200 mg/m ² , about 220 mg/m ² , about 240 mg/m ² , about 260 mg/m ² , about 280 mg/m ² , about 300 mg/m ² , about 320 mg/m ² , about 340 mg/m ² , about 360 mg/m ² , about 380 mg/m ² , about 400 mg/m ² , about 420 mg/m ² , about 440 mg/m ² , about 460 mg/m ² , about 480 mg/m ² , about 500 mg/m ² , about 520 mg/m ² , about 540 mg/m ² , about 560 mg/m ² , about 580 mg/m ² , about 600 mg/m ² , about 620 mg/m ² , about 640 mg/m ² , about 660 mg/m ² , about 680 mg/m ² , about 700 mg/m ² , about 720 mg/m ² , about 740 mg/m ² , about 760 mg/m ² , about 780 mg/m ² , about 800 mg/m ² , about 820 mg/m ² , about 840 mg/m ² , about 860 mg/m ² , about 880 mg/m ² , about 900 mg/m ² , about 920 mg/m ² , about 940 mg/m ² , about 960 mg/m ² , about 980 mg/m ² , about 1000 mg/m ² , about 1020 mg/m ² , about 1040 mg/m ² , about 1060 mg/m ² , about 1080 mg/m ² , about 1100 mg/m ² , about 1120 mg/m ² , about 1140 mg/m ² , about 1160 mg/m ² , about 1180 mg/m ² , about 1200 mg/m ² , about 1220 mg/m ² , about 1240 mg/m ² , about 1260 mg/m ² , about 1280 mg/m ² , about 1300 mg/m ² , about 1320 mg/m ² , about 1340 mg/m ² , about 1360 mg/m ² , about 1380 mg/m ² , about 1400 mg/m ² , about 1420 mg/m ² , about 1440 mg/m ² , about 1460 mg/m ² , about 1480 mg/m ² , or about 1500 mg/m ² . [0629] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 500 mg/m ² . 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0630] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 600 mg/m ² . [0631] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 700 mg/m ² . [0632] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 800 mg/m ² . [0633] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 900 mg/m ² . [0634] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 1000 mg/m ² . [0635] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 1100 mg/m ² . [0636] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 1200 mg/m ² . [0637] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 1300 mg/m ² . [0638] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 1400 mg/m ² . [0639] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 1500 mg/m ² . [0640] In some embodiments, the amount of the second therapeutic agent (e.g., capecitabine and gemcitabine) that is administered in combination with Compound A (e.g., human dosage) is about 50 mg/day, about 60 mg/day, about 70 mg/day, about 80 mg/day, about 90 mg/day, 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 about 100 mg/day, about 110 mg/day, about 120 mg/day, about 130 mg/day, about 140 mg/day, about 150 mg/day, about 160 mg/day, about 170 mg/day, about 180 mg/day, about 190 mg/day, about 200 mg/day, about 210 mg/day, about 220 mg/day, about 230 mg/day, about 240 mg/day, about 250 mg/day, about 260 mg/day, about 270 mg/day, about 280 mg/day, about 290 mg/day, about 300 mg/day, about 310 mg/day, about 320 mg/day, about 330 mg/day, about 340 mg/day, about 350 mg/day, about 360 mg/day, about 370 mg/day, about 380 mg/day, about 390 mg/day, about 400 mg/day, about 410 mg/day, about 420 mg/day, about 430 mg/day, about 440 mg/day, about 450 mg/day, about 460 mg/day, about 470 mg/day, about 480 mg/day, about 490 mg/day, about 500 mg/day, about 510 mg/day, about 520 mg/day, about 530 mg/day, about 540 mg/day, about 550 mg/day, about 560 mg/day, about 570 mg/day, about 580 mg/day, about 590 mg/day, about 600 mg/day, about 610 mg/day, about 620 mg/day, about 630 mg/day, about 640 mg/day, about 650 mg/day, about 660 mg/day, about 670 mg/day, about 680 mg/day, about 690 mg/day, about 700 mg/day, about 710 mg/day, about 720 mg/day, about 730 mg/day, about 740 mg/day, about 750 mg/day, about 760 mg/day, about 770 mg/day, about 780 mg/day, about 790 mg/day, about 800 mg/day, about 810 mg/day, about 820 mg/day, about 830 mg/day, about 840 mg/day, about 850 mg/day, about 860 mg/day, about 870 mg/day, about 880 mg/day, about 890 mg/day, about 900 mg/day, about 910 mg/day, about 920 mg/day, about 930 mg/day, about 940 mg/day, about 950 mg/day, about 960 mg/day, about 970 mg/day, about 980 mg/day, about 990 mg/day, about 1000 mg/day, about 1010 mg/day, about 1020 mg/day, about 1030 mg/day, about 1040 mg/day, about 1050 mg/day, about 1060 mg/day, about 1070 mg/day, about 1080 mg/day, about 1090 mg/day, about 1100 mg/day, about 1110 mg/day, about 1120 mg/day, about 1130 mg/day, about 1140 mg/day, about 1150 mg/day, about 1160 mg/day, about 1170 mg/day, about 1180 mg/day, about 1190 mg/day, about 1200 mg/day, about 1210 mg/day, about 1220 mg/day, about 1230 mg/day, about 1240 mg/day, about 1250 mg/day, about 1260 mg/day, about 1270 mg/day, about 1280 mg/day, about 1290 mg/day, about 1300 mg/day, about 1310 mg/day, about 1320 mg/day, about 1330 mg/day, about 1340 mg/day, about 1350 mg/day, about 1360 mg/day, about 1370 mg/day, about 1380 mg/day, about 1390 mg/day, about 1400 mg/day, about 1410 mg/day, about 1420 mg/day, about 1430 mg/day, about 1440 mg/day, about 1450 mg/day, about 1460 mg/day, about 1470 mg/day, about 1480 mg/day, about 1490 mg/day, about 1500 mg/day, about 1510 mg/day, about 1520 mg/day, about 1530 mg/day, about 1540 mg/day, about 1550 mg/day, about 1560 mg/day, about 1570 mg/day, about 1580 mg/day, about 1590 mg/day, about 1600 mg/day, about 1610 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 mg/day, about 1620 mg/day, about 1630 mg/day, about 1640 mg/day, about 1650 mg/day, about 1660 mg/day, about 1670 mg/day, about 1680 mg/day, about 1690 mg/day, about 1700 mg/day, about 1710 mg/day, about 1720 mg/day, about 1730 mg/day, about 1740 mg/day, about 1750 mg/day, about 1760 mg/day, about 1770 mg/day, about 1780 mg/day, about 1790 mg/day, about 1800 mg/day, about 1810 mg/day, about 1820 mg/day, about 1830 mg/day, about 1840 mg/day, about 1850 mg/day, about 1860 mg/day, about 1870 mg/day, about 1880 mg/day, about 1890 mg/day, about 1900 mg/day, about 1910 mg/day, about 1920 mg/day, about 1930 mg/day, about 1940 mg/day, about 1950 mg/day, about 1960 mg/day, about 1970 mg/day, about 1980 mg/day, about 1990 mg/day, or about 2000 mg/day. [0641] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein. [0642] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein, for one day per week. [0643] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein, for two days per week. [0644] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein, for three days per week. [0645] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein, for four days per week. [0646] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein, for five days per week. [0647] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein, for six days per week. [0648] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein, for seven days per week. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0649] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein, for two weeks. [0650] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein, for three weeks. [0651] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered once daily, for example, at any of the dosage described herein, for four weeks. [0652] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein. [0653] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein, for one day per week. [0654] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein, for two days per week. [0655] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein, for three days per week. [0656] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein, for four days per week. [0657] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein, for five days per week. [0658] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein, for six days per week. [0659] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein, for seven days per week. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0660] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein, for two weeks. [0661] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein, for three weeks. [0662] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily, for example, at any of the dosage described herein, for four weeks. [0663] In some embodiments, Compound A is administered once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered on a 14 day on/7 day off schedule, for example, at any of the dosage described herein. [0664] In some embodiments, Compound A is administered orally once daily and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered orally on a 14 day on/7 day off schedule, for example, at any of the dosage described herein. [0665] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, once every other day. [0666] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, once every other day for four days. [0667] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, once every other day for 6 days. [0668] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, once every other day for two weeks. [0669] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, once every other day for three weeks. [0670] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, once every other day for four weeks. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0671] In some embodiment, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, without a dosing holiday. [0672] In some embodiment, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, followed by a dosing holiday. [0673] In some embodiment, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, for two weeks followed by a dosing holiday. [0674] In some embodiment, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, for three weeks followed by a dosing holiday. [0675] In some embodiment, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, for four weeks followed by a dosing holiday. [0676] In some embodiment, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, followed by a 7-day dosing holiday. [0677] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, followed by a 14-day dosing holiday. [0678] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, followed by a 21-day dosing holiday. [0679] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, followed by a 28-day dosing holiday. [0680] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, followed by a 35-day dosing holiday. [0681] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, followed by a 42-day dosing holiday. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0682] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered, for example, at any of the dosage described herein, followed by a 49-day dosing holiday. [0683] In some embodiments, Compound A and the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered according to different dosing regimen. [0684] In some embodiments, Compound A is administered on consecutive days for a first period of time and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered on consecutive days for a second period of time. In some embodiments, the first period of time is different from the second period of time. In some embodiments, the first period of time is longer than the second period of time. In some embodiments, the first period of time is 21 days or 28 days, and the second period of time is 7 days or 14 days. In some embodiments, the first period of time and the second period of time start at the same time. In some embodiments, the first period of time and the second period of time start at different time. In some embodiments, the first period of time starts before the second period of time. In some embodiments, the first period of time starts after the second period of time. [0685] In some embodiments, Compound A is administered at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day) on consecutive days for 21 days, and the second therapeutic agent is capecitabine and is administered at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0686] In some embodiments, Compound A is administered at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day) on consecutive days for 21 days, and the second therapeutic agent is capecitabine and is administered at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) twice daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0687] In some embodiments, Compound A is orally administered at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day) on consecutive days for 21 days, and the second therapeutic agent is capecitabine and is orally administered at any of the dosage 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) twice daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0688] In some embodiments, Compound A is administered at about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day on consecutive days for 21 days, and the second therapeutic agent is capecitabine and is administered at about 1000 mg/m ² daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0689] In some embodiments, Compound A is administered at about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day on consecutive days for 21 days, and the second therapeutic agent is capecitabine and is administered at about 1000 mg/m ² twice daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0690] In some embodiments, Compound A is orally administered at about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day on consecutive days for 21 days, and the second therapeutic agent is capecitabine and is orally administered at about 1000 mg/m ² twice daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0691] In some embodiments, Compound A is administered at about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day on consecutive days for 21 days, and the second therapeutic agent is 5-FU and is administered at about 1000 mg/m ² twice daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0692] In some embodiments, Compound A is administered on consecutive days for a first period of time and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered once weekly for a second period of time. In some embodiments, the first period of time is different from the second period of time. In some embodiments, the first period of time is longer than the second period of time. In some embodiments, the first period of time is 21 days or 28 days, and the second period of time is three weeks or four weeks. In some embodiments, the first period of time and the second period of time start at the same time. In some embodiments, the first period of time and the second period of time start at different time. In some embodiments, the first period of time starts before the second period of time. In some embodiments, the first period of time starts after the second period of time. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0693] In some embodiments, Compound A is administered on consecutive days for a first period of time and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily for a second period of time. In some embodiments, the first period of time is different from the second period of time. In some embodiments, the first period of time is longer than the second period of time. In some embodiments, the first period of time is 21 days or 28 days, and the second period of time is two weeks, three weeks or four weeks. In some embodiments, the first period of time and the second period of time start at the same time. In some embodiments, the first period of time and the second period of time start at different time. In some embodiments, the first period of time starts before the second period of time. In some embodiments, the first period of time starts after the second period of time. [0694] In some embodiments, Compound A is administered at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day) on consecutive days for 28 days, and the second therapeutic agent is capecitabine and is administered at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) once weekly on the first day of each week for three weeks. In some embodiments, the 3-week period starts at the same time as the 28-day period, i.e., Day 1 of the 3-week period is the Day 1 of the 28-day period. [0695] In some embodiments, Compound A is administered at about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day on consecutive days for 28 days, and the second therapeutic agent is capecitabine and is administered at about 1000 mg/m ² once weekly on the first day of each week for three weeks. In some embodiments, the 3-week period starts at the same time as the 28-day period, i.e., Day 1 of the 3-week period is the Day 1 of the 28-day period. [0696] In some embodiments, Compound A is administered at any of the dosages described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day) on consecutive days for 21-days, and the second therapeutic agent is capecitabine and is administered at any of the dosages described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) twice daily for two weeks every 21-days. In some embodiments, the 21-days period of Compound A starts at the same time as the 21-days period of the second therapeutic agent, i.e., Day 1 of 21-days period of Compound A and Day 1 of the 21-days period of the second therapeutic agent is the same. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0697] In some embodiments, Compound A is administered at about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day on consecutive days for 21 days, and the second therapeutic agent is capecitabine and is administered at about 1000 mg/m ² twice daily for two weeks every 21-days. In some embodiments, the 21-days period of Compound A starts at the same time as the 21-days period of the second therapeutic agent, i.e., Day 1 of 21-days period of Compound A and Day 1 of the 21-days period of the second therapeutic agent is the same. [0698] In some embodiments, Compound A is administered at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day) on consecutive days for 21 days, and the second therapeutic agent is gemcitabine and is administered at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0699] In some embodiments, Compound A is administered at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day) on consecutive days for 21 days, and the second therapeutic agent is gemcitabine and is administered at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) twice daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0700] In some embodiments, Compound A is administered at about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day on consecutive days for 21 days, and the second therapeutic agent is gemcitabine and is administered at about 1000 mg/m ² daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0701] In some embodiments, Compound A is administered at about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day on consecutive days for 21 days, and the second therapeutic agent is gemcitabine and is administered at about 1000 mg/m ² twice daily on consecutive days for 14 days. In some embodiments, the 14-day period starts at the same time as the 21-day period. [0702] In some embodiments, Compound A is administered at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 about 500 mg/day, or about 600 mg/day) on consecutive days for 28 days, and the second therapeutic agent is gemcitabine and is administered at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) once weekly on the first day of each week for three weeks. In some embodiments, the 3-week period starts at the same time as the 28-day period, i.e., Day 1 of the 3-week period is the Day 1 of the 28-day period. [0703] In some embodiments, Compound A is administered at about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day on consecutive days for 28 days, and the second therapeutic agent is gemcitabine and is administered at about 1000 mg/m ² once weekly on the first day of each week for three weeks. In some embodiments, the 3-week period starts at the same time as the 28-day period, i.e., Day 1 of the 3-week period is the Day 1 of the 28-day period. [0704] In some embodiments, Compound A is administered at any of the dosages described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day) on consecutive days for 21-days, and the second therapeutic agent is gemcitabine and is administered at any of the dosages described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) twice daily for two weeks every 21-days. In some embodiments, the 21-days period of Compound A starts at the same time as the 21-days period of the second therapeutic agent, i.e., Day 1 of 21-days period of Compound A and Day 1 of the 21-days period of the second therapeutic agent is the same. [0705] In some embodiments, Compound A is administered at about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day on consecutive days for 21 days, and the second therapeutic agent is gemcitabine and is administered at about 1000 mg/m ² twice daily for two weeks every 21-days. In some embodiments, the 21-days period of Compound A starts at the same time as the 21-days period of the second therapeutic agent, i.e., Day 1 of 21-days period of Compound A and Day 1 of the 21-days period of the second therapeutic agent is the same. Dosing Cycle [0706] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, or 49 days. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0707] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, or 49 days and wherein Compound A is administered daily. [0708] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, or 49 days and wherein the second therapeutic agent is administered daily. [0709] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days, wherein Compound A is administered once daily for 21 days and the second therapeutic agent is administered twice daily for two weeks every 21 days. [0710] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, or 49 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered weekly. [0711] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, or 49 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered at least once per dosing cycle. [0712] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, or 49 days and wherein Compound A is administered orally. In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, or 49 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered orally. [0713] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, or 49 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered intravenously. [0714] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 7 days, 14 days, 21 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 days, 28 days, 35 days, 42 days, or 49 days and wherein Compound A and the second therapeutic agent are administered orally. [0715] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days, wherein Compound A is orally administered once daily for 21 days and the second therapeutic agent is orally administered twice daily for two weeks every 21 days. [0716] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days. [0717] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days. [0718] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein Compound A is administered daily. [0719] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein Compound A is administered once daily. [0720] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered daily for the first 14 days. [0721] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily for the first 14 days. [0722] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days and wherein Compound A is administered daily. [0723] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered on Day 1, Day 8 and Day 15. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0724] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein Compound A is orally administered daily. [0725] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein Compound A is orally administered once daily. [0726] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is orally administered daily for the first 14 days. [0727] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is orally administered twice daily for the first 14 days. [0728] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days and wherein Compound A is orally administered daily. [0729] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is orally administered on Day 1, Day 8 and Day 15. [0730] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein Compound A is administered daily at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day). In some embodiments, the second therapeutic agent is capecitabine. [0731] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein Compound A is administered daily at any of the dosage described herein (e.g., about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day). In some embodiments, the second therapeutic agent is capecitabine. [0732] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered daily for the first 14 days at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ). In some embodiments, the second therapeutic agent is capecitabine. [0733] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily for the first 14 days at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ). In some embodiments, the second therapeutic agent is capecitabine. [0734] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered daily for the first 14 days at about 1000 mg/m ² . In some embodiments, the second therapeutic agent is capecitabine. [0735] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily for the first 14 days at about 1000 mg/m ² . In some embodiments, the second therapeutic agent is capecitabine. [0736] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days, wherein Compound A is administered daily at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day), and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered daily for the first 14 days at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ). In some embodiments, the second therapeutic agent is capecitabine. [0737] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days, wherein Compound A is administered once daily at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day), and the second therapeutic agent (e.g., capecitabine and gemcitabine) is 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 administered twice daily for the first 14 days at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ). In some embodiments, the second therapeutic agent is capecitabine. [0738] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days, wherein Compound A is administered daily at any of the dosage described herein (e.g., about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day), and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered daily for the first 14 days at about 1000 mg/m ² . In some embodiments, the second therapeutic agent is capecitabine. [0739] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 21 days, wherein Compound A is administered once daily at any of the dosage described herein (e.g., about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day), and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered twice daily for the first 14 days at about 1000 mg/m ² . In some embodiments, the second therapeutic agent is capecitabine. [0740] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days and wherein Compound A is administered daily at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day). In some embodiments, the second therapeutic agent is gemcitabine. [0741] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days and wherein Compound A is administered daily at any of the dosage described herein (e.g., about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day). In some embodiments, the second therapeutic agent is gemcitabine. [0742] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) on Day 1, Day 8 and Day 15. In some embodiments, the second therapeutic agent is gemcitabine. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0743] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days and wherein the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered at about 1000 mg/m ² on Day 1, Day 8 and Day 15. In some embodiments, the second therapeutic agent is gemcitabine. [0744] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days, wherein Compound A is administered daily at any of the dosage described herein (e.g., about 100 mg/day, about 200 mg/day, about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day), and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered at any of the dosage described herein (e.g., about 800 mg/m ² , about 900 mg/m ² , about 1000 mg/m ² , about 1100 mg/m ² , or about 1200 mg/m ² ) on Day 1, Day 8 and Day 15. In some embodiments, the second therapeutic agent is gemcitabine. [0745] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered with a dosing cycle of 28 days, wherein Compound A is administered daily at any of the dosage described herein (e.g., about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day), and the second therapeutic agent (e.g., capecitabine and gemcitabine) is administered at about 1000 mg/m ² on Day 1, Day 8 and Day 15. In some embodiments, the second therapeutic agent is gemcitabine. [0746] In some embodiments, Compound A and/or the second therapeutic agent (e.g., capecitabine and gemcitabine) are administered as provided in Table A below. Table A. Dosing Regimen Note: PO = orally, QD = once a day, BID = twice a day, IV = intravenous, and D = day [0747] In some embodiments, Compound A and capecitabine are administered as provided in Table B below. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 Table B. Dosing Regimen [0748] In some embodiments, Compound A and/or the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU are administered, wherein Compound A is administered daily at any of the dosage described herein (e.g., about 300 mg/day, about 400 mg/day, about 500 mg/day, or about 600 mg/day), and wherein the second therapeutic agent selected from capecitabine, gemcitabine and 5-FU: (a) is administered at 400 mg/m ² intravenous bolus on Day 1, followed by 2400 mg/m ² to 3000 mg/m ² intravenously as a continuous infusion over 46 hours every two weeks; (b) if administered in a bolus dosing regimen in combination with Compound A, is 500 mg/m ² by intravenous bolus on Days 1, 8, 15, 22, 29, and 36 in 8-week cycles; (c) is administered as a component of a cyclophosphamide-based multidrug regimen, is 500 mg/m ² or 600 mg/m ² intravenously on Days 1 and 8 every 28 days for 6 cycles; (d) is administered as a component of a platinum-containing multidrug chemotherapy regimen, is 200 mg/m ² to 1000 mg/m ² intravenously as a continuous infusion over 24 hours. The frequency of dosing in each cycle and the length of each cycle will depend on the dose of fluorouracil and the specific regimen administered; or (e) is administered as an infusional regimen in combination with Compound A or as a component of a multidrug chemotherapy regimen, is 400 mg/m ² intravenous bolus on Day 1, followed by 2400 mg/m ² intravenously as a continuous infusion over 46 hours every two weeks. Pharmaceutical Compositions [0749] The combination disclosed therein comprises Compound A and a second therapeutic agent. In some embodiments, the combination disclosed therein comprises Compound A and capecitabine. In some embodiments, the combination disclosed therein comprises Compound A and gemcitabine. [0750] The pharmaceutical composition of the present disclosure comprises Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent, and a pharmaceutically acceptable carrier or diluent. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0751] The pharmaceutical composition of the present disclosure comprises Compound A, or a pharmaceutically acceptable salt thereof, in combination with capecitabine, and a pharmaceutically acceptable carrier or diluent. [0752] The pharmaceutical composition of the present disclosure comprises Compound A, or a pharmaceutically acceptable salt thereof, in combination with gemcitabine, and a pharmaceutically acceptable carrier or diluent. [0753] “Pharmaceutically acceptable carrier” and “pharmaceutically acceptable diluent” refer to a substance that aids the formulation and/or administration of an active agent to and/or absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the subject. Non- limiting examples of pharmaceutically acceptable carriers and/or diluents include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer’s solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with or interfere with the activity of the compounds provided herein. One of ordinary skill in the art will recognize that other pharmaceutical excipients are suitable for use with disclosed compounds. [0754] The pharmaceutical compositions of the present teachings optionally include one or more pharmaceutically acceptable carriers and/or diluents therefor, such as lactose, starch, cellulose and dextrose. Other excipients, such as flavoring agents; sweeteners; and preservatives, such as methyl, ethyl, propyl and butyl parabens, can also be included. More complete listings of suitable excipients can be found in the Handbook of Pharmaceutical Excipients (5 ^th Ed., Pharmaceutical Press (2005)). A person skilled in the art would know how to prepare formulations suitable for various types of administration routes. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington’s Pharmaceutical Sciences (2003 - 20th edition) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19) published in 1999. The carriers, diluents and/or excipients are “acceptable” in the sense of being compatible with 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 the other ingredients of the pharmaceutical composition and not deleterious to the recipient thereof. [0755] The term “dosage holiday”, also referred to as “drug holiday,” refers to a period of time wherein the subject is not administered or administered at a lower dosage of the therapeutic (i.e., Compound A, capecitabine or gemcitabine). The timing of a dosage holiday depends on the timing of the regular dosing regimen and the purpose for taking the dosage holiday (e.g., to regain drug sensitivity and/or to reduce unwanted side effects of continuous, long- term administration). In some embodiments, the dosage holiday may be a reduction in the dosage of the drug (e.g., to below the therapeutically effective amount for a certain interval of time). In other embodiments, administration of the dosage is stopped for a certain interval of time before administration is started again at the same or different dosing regimen (e.g., at a lower or higher dose and/or frequency of administration). A dosage holiday of the disclosure may thus be selected from a wide range of time-periods and dosage regimens. Additional Aspects of Methods of Treatment [0756] Another embodiment is a method of treating and/or preventing a cancer by administering to the subject an effective amount of Compound A, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent, or the corresponding pharmaceutical composition. In one aspect, the cancer is solid cancer. In another aspect, the cancer is selected from the group consisting of lymphoma, leukemia, and a plasma cell neoplasm. In yet another aspect, the cancer selected from the group consisting of carcinoma and sarcoma. [0757] In some embodiments, the cancer to be treated is pancreatic cancer. [0758] In some embodiments, the cancer to be treated is ovarian cancer. [0759] In some embodiments, the cancer to be treated is platinum-resistant ovarian cancer. [0760] In some embodiments, the cancer to be treated is platinum-resistant advanced ovarian cancer. [0761] In some embodiments, the cancer to be treated is platinum refractory ovarian cancer. [0762] In some embodiments, the cancer to be treated is head and neck cancer. [0763] In some embodiments, the cancer to be treated is sarcoma. [0764] In some embodiments, the cancer to be treated is soft tissue sarcoma. [0765] In some embodiments, the cancer is breast cancer, colorectal cancer, recurrent squamous cell carcinoma of the head and neck cancer (HNSCC), non-small cell lung cancer (NSCLC), ovarian cancer, soft-tissue sarcoma, or pancreatic cancer. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0766] In some embodiments, the cancer is platinum-resistant ovarian cancer. [0767] In some embodiments, the cancer is platinum-resistant advanced ovarian cancer. [0768] In some embodiments, the cancer is platinum refractory ovarian cancer. [0769] In some embodiments, the pancreatic cancer is exocrine pancreatic cancer. In some embodiments, the exocrine pancreatic cancer is adenocarcinoma. In some embodiments, the exocrine pancreatic cancer is squamous cell carcinoma. In some embodiments, the exocrine pancreatic cancer is adenosquamous carcinoma. In some embodiments, the exocrine pancreatic cancer is colloid carcinoma. [0770] In some embodiments, the pancreatic cancer is neuroendocrine pancreatic cancer. In some embodiments, the neuroendocrine pancreatic cancer is a nonfunctioning neuroendocrine tumor. In some embodiments, the neuroendocrine pancreatic cancer is gastrinoma. In some embodiments, the neuroendocrine pancreatic cancer is insulinoma. In some embodiments, the neuroendocrine pancreatic cancer is glucagonoma. [0771] In some embodiments, the neuroendocrine pancreatic cancer is a VIPoma (i.e., an islet cell tumor which affects the vasoactive intestinal peptides). In some embodiments, the neuroendocrine pancreatic cancer is a somatostatinoma (i.e., an islet cell tumor which affects the somatostatin). [0772] In some embodiments, the cancer is adenocarcinoma of the colon and rectum, adenocarcinoma of the breast, gastric adenocarcinoma, or pancreatic adenocarcinoma. [0773] In some embodiments, the pancreatic cancer is benign precancerous lesions. [0774] In some embodiments, the cancer to be treated is a lymphoma. Lymphomas which can be treated by the disclosed methods and combinations of the present application include Non-Hodgkin’s lymphoma; Burkitt’s lymphoma; small lymphocytic lymphoma; lymphoplasmacytic lymphoma; MALT lymphoma; follicular lymphoma; diffuse large B-cell lymphoma; and T-cell lymphoma. [0775] Lymphoma is a malignancy in the lymphatic cells of the immune system (e.g. B cells, T cells, or natural killer (NK) cells). Lymphomas often originate in the lymph nodes and present as solid tumors. They can metastasize to other organs such as the brain, bone, or skin. Extranodal sites are often located in the abdomen. Lymphomas are closely related to the lymphoid leukemia and in some cases a particular form of cancer is categorized as both a lymphoma and a leukemia. [0776] Leukemias which can be treated by the disclosed methods and combinations of the present application include acute lymphoblastic leukemia (ALL); Burkitt’s leukemia; B-cell 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 leukemia; B-cell acute lymphoblastic leukemia; chronic lymphocytic leukemia (CLL); acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML); and T-cell acute lymphoblastic leukemia (T-ALL). [0777] In some embodiments the cancer to be treated is B-cell neoplasms, B-cell leukemia, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Burkitt's leukemia, acute myelogenous leukemia and/or T-ALL. The maturation of B cells most typically ceases or substantially decreases when the foreign antigen has been neutralized. Occasionally, however, proliferation of a particular B cell will continue unabated; such proliferation can result in a cancer referred to as "B-cell lymphoma" or a "B- cell leukemia." In some embodiments the cancer to be treated is chronic lymphocytic leukemia (CLL) or chronic myelogenous leukemia (CML). [0778] In some embodiments the cancer to be treated is a plasma cell neoplasm. Examples for plasma cell neoplasms include multiple myeloma; plasma cell myeloma; plasma cell leukemia and plasmacytoma. [0779] Carcinomas which can be treated by the disclosed methods and combinations of the present application include colon cancer; liver cancer; gastric cancer; intestinal cancer; esophageal cancer; breast cancer; ovarian cancer (e.g. platinum-resistant ovarian cancer); head and neck cancer; lung cancer; and thyroid cancer. [0780] Sarcomas which can be treated by the disclosed methods and combinations of the present application include soft tissue sarcoma and bone sarcoma. [0781] Some cancers that can be treated by the disclosed methods and combinations of the present application include cancer of the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestine, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus. In addition, the cancer may be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; sarcomas; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; Paget’s disease, mammary; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma w/squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant; androblastoma, malignant; sertoli cell carcinoma; Leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extra-mammary paraganglioma, malignant; pheochromocytoma; glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malignant melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; brenner tumor, malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; struma ovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; Kaposi’s sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone; Ewing’s sarcoma; odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant; ameloblastic fibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant lymphoma; Hodgkin’s disease; Hodgkin’s; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 lymphoma, follicular; mycosis fungoides; other specified non-Hodgkin’s lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia. Methods of Administration and Dosage Forms [0782] The terms “administer”, “administering”, “administration”, and the like, as used herein, refer to methods that may be used to enable delivery of compositions to the desired site of biological action. These methods include, but are not limited to, intraarticular (in the joints), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, orally, topically, intrathecally, inhalationally, transdermally, rectally, and the like. Administration techniques that can be employed with the agents and methods described herein are found in e.g., Goodman and Gilman, The Pharmacological Basis of Therapeutics, current ed.; Pergamon; and Remington’s, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa. [0783] In addition, Compound A and the second therapeutic agent (e.g., capecitabine and gemcitabine) can be co-administered with other therapeutic agents. As used herein, the terms “co-administration”, “administered in combination with”, and their grammatical equivalents, are meant to encompass administration of two or more therapeutic agents to a single subject, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different times. In some embodiments the one or more compounds described herein will be co-administered with other agents. These terms encompass administration of two or more agents to the subject so that both agents and/or their metabolites are present in the subject at the same time. They include simultaneous administration in separate compositions, administration at different times in separate compositions, and/or administration in a composition in which both agents are present. Thus, in some embodiments, the compounds described herein and the other agent(s) are administered in a single composition. In some embodiments, the compounds described herein and the other agent(s) are admixed in the composition. [0784] The particular mode of administration and the dosage regimen will be selected by the attending clinician, taking into account the particulars of the case (e.g., the subject, the disease, the disease state involved, the particular treatment). Treatment can involve daily or 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 multi-daily or less than daily (such as weekly or monthly etc.) doses over a period of a few days to months, or even years. However, a person of ordinary skill in the art would immediately recognize appropriate and/or equivalent doses looking at dosages of approved compositions for treating solid cancer using the disclosed combination of Compound A and a second therapeutic agent (e.g., capecitabine and gemcitabine) for guidance. [0785] The combination or the corresponding pharmaceutical composition taught herein can be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The combination of the present teachings may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump or transdermal administration and the pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal and topical modes of administration. Parenteral administration can be by continuous infusion over a selected period of time. [0786] The pharmaceutical composition of the disclosure is formulated to be compatible with its intended route of administration. In an embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to human beings. In preferred embodiments, the pharmaceutical composition is formulated for intravenous administration. [0787] Typically, for oral therapeutic administration, a combination of the present teachings may be incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. [0788] Typically for parenteral administration, solutions of a combination of the present teachings can generally be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. [0789] Typically, for injectable use, sterile aqueous solutions or dispersion of, and sterile powders of, a combination described herein for the extemporaneous preparation of sterile injectable solutions or dispersions are appropriate. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0790] All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. Citation of publications and patent documents is not intended as an admission that any is pertinent prior art, nor does it constitute any admission as to the contents or date of the same. The invention having now been described by way of written description, those of skill in the art will recognize that the invention can be practiced in a variety of embodiments and that the foregoing description and examples below are for purposes of illustration and not limitation of the claims that follow. EXEMPLARY EMBODIMENTS [0791] Exemplary Embodiment 1. A method of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of Compound A: (Compound A), and an effective amount of a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and fluorouracil (5-FU). [0792] Exemplary Embodiment 2. A method of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject a combination comprising an effective amount of Compound A: (Compound A), and an effective amount of a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and fluorouracil (5-FU). [0793] Exemplary Embodiment 3. A method of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising an effective amount of Compound A: 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 and a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS- 010759 and fluorouracil (5-FU). [0794] Exemplary Embodiment 4. The method of any one of Exemplary Embodiments 1- 3, wherein Compound A is administered at a dosage ranging from about 100 mg to about 400 mg once daily. [0795] Exemplary Embodiment 5. The method of any one of Exemplary Embodiments 1- 4, wherein Compound A is administered at a dosage ranging from about 200 mg to about 400 mg once daily. [0796] Exemplary Embodiment 6. The method of any one of Exemplary Embodiments 1- 5, wherein Compound A is administered at a dosage of about 400 mg once daily. [0797] Exemplary Embodiment 7. The method of any one of Exemplary Embodiments 1- 6, wherein the second therapeutic agent is capecitabine. [0798] Exemplary Embodiment 8. The method of Exemplary Embodiment 7, wherein the capecitabine is administered at a dosage of about 1,000 mg/m ² orally once daily. [0799] Exemplary Embodiment 9. The method of Exemplary Embodiment 7, wherein the capecitabine is administered at a dosage of about 1,000 mg/m ² orally twice daily. [0800] Exemplary Embodiment 10. The method of any one of Exemplary Embodiments 1- 9, wherein the subject is administered with Compound A for a period of 21 days consecutively. [0801] Exemplary Embodiment 11. The method of any one of Exemplary Embodiments 1- 10, wherein the subject is administered with capecitabine for a period of 14 days consecutively. [0802] Exemplary Embodiment 12. The method of any one of Exemplary Embodiment 10- 11, wherein the subject is administered with capecitabine for the first 14 days of the 21-day period during which Compound A is administered. [0803] Exemplary Embodiment 13. The method of any one of Exemplary Embodiments 1- 6, wherein the second therapeutic agent is gemcitabine. [0804] Exemplary Embodiment 14. The method of Exemplary Embodiment 13, wherein the gemcitabine is administered at a dosage of about 1,000 mg/m ² intravenously. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0805] Exemplary Embodiment 15. The method of any one of Exemplary Embodiments 1- 6 and 13-14, wherein the subject is administered with Compound A for a period of 28 days consecutively. [0806] Exemplary Embodiment 16. The method of any one of Exemplary Embodiments 1- 6 and 13-15, wherein the subject is administered with gemcitabine once weekly for three weeks. [0807] Exemplary Embodiment 17. The method of any one of Exemplary Embodiments 15-16, wherein the subject is administered with gemcitabine on the first day, the eighth day, and the fifteenth day of the 28-day period during which Compound A is administered. [0808] Exemplary Embodiment 18. The method of any one of Exemplary Embodiments 1- 6, wherein the second therapeutic agent is 5-FU. [0809] Exemplary Embodiment 19. The method of Exemplary Embodiment 18, wherein the 5-FU is administered at a dosage of about 200 mg/m ² , about 400 mg/m ² , about 500 mg/m ² , about 600 mg/m ² , about 1000 mg/m ² , about 2400 mg/m ² , or about 3000 mg/m ² , intravenously. [0810] Exemplary Embodiment 20. The method of Exemplary Embodiment 18, wherein the 5-FU is administered in an infusional regimen at a dosage of about 400 mg/m ² by intravenous bolus on Day 1, followed by at about 2400 mg/m ² to about 3000 mg/m ² continuous intravenous infusion over 46 hours every two weeks. [0811] Exemplary Embodiment 21. The method of Exemplary Embodiment 18, wherein the 5-FU is administered in a bolus dosing regimen at a dosage of about 500 mg/m ² by intravenous bolus on Days 1, 8, 15, 22, 29, and 36 in 8-week cycles. [0812] Exemplary Embodiment 22. The method of Exemplary Embodiment 18, wherein the 5-FU is administered at a dosage of about 500 mg/m ² or about 600 mg/m ² intravenously on Days 1 and 8 every 28 days for 6 cycles, optionally as a component of a cyclophosphamide-based multidrug regimen. [0813] Exemplary Embodiment 23. The method of Exemplary Embodiment 18, wherein the 5-FU is administered at a dosage of about 200 mg/m ² to about 1000 mg/m ² intravenously as a continuous infusion over 24 hours, optionally as a component of a platinum-containing multidrug chemotherapy regimen. [0814] Exemplary Embodiment 24. The method of Exemplary Embodiment 18, wherein the 5-FU is administered in an infusional regimen at a dosage of about 400 mg/m ² by intravenous bolus on Day 1, followed by at about 2400 mg/m ² continuous intravenous 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 infusion over 46 hours every two weeks, optionally as a component of a multidrug chemotherapy regimen. [0815] Exemplary Embodiment 25. A combination comprising Compound A, (Compound A), or a pharmaceutically acceptable salt thereof, and a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and fluorouracil (5-FU). [0816] Exemplary Embodiment 26. A combination comprising Compound A, or a pharmaceutically acceptable salt thereof, and a second therapeutic agent selected from capecitabine, wherein Compound A is administered at a dosage from about 100 mg to about 400 mg orally once daily and capecitabine is administered at a dosage of about 1,000 mg/m ² orally once daily for 14 days consecutively, optionally for the first 14 days of a period of 21 days. [0817] Exemplary Embodiment 27. A method of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising Compound A, or a pharmaceutically acceptable salt thereof, and a second therapeutic agent selected from capecitabine, wherein Compound A is administered at a dosage from about 100 mg to about 400 mg orally once daily and capecitabine is administered at a dosage of about 1,000 mg/m ² orally once daily for 14 days consecutively, optionally for the first 14 days of a period of 21 days. [0818] Exemplary Embodiment 28. A combination comprising Compound A, 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 or a pharmaceutically acceptable salt thereof, and capecitabine, wherein Compound A is administered at a dosage from about 100 mg to about 400 mg orally once daily and capecitabine is administered at a dosage of about 1,000 mg/m ² orally twice daily for 14 days consecutively, optionally for the first 14 days of a period of 21 days. [0819] Exemplary Embodiment 29. A method of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising Compound A, (Compound A), or a pharmaceutically acceptable salt thereof, and capecitabine, wherein Compound A is administered at a dosage from about 100 mg to about 400 mg orally once daily and capecitabine is administered at a dosage of about 1,000 mg/m ² orally twice daily for 14 days consecutively, optionally for the first 14 days of a period of 21 days. [0820] Exemplary Embodiment 30. The method of any one of Exemplary Embodiments 1- 24, 27 and 29, wherein the cancer is solid cancer. [0821] Exemplary Embodiment 31. The method of any one of Exemplary Embodiments 1- 24, 27 and 29, wherein the cancer is lymphoma, leukemia, or a plasma cell neoplasm. [0822] Exemplary Embodiment 32. The method of any one of Exemplary Embodiments 1- 24, 27 and 29, wherein the cancer is carcinoma or sarcoma. [0823] Exemplary Embodiment 33. The method of any one of Exemplary Embodiments 1- 24, 27 and 29, wherein the cancer is colon cancer, liver cancer, gastric cancer, intestinal cancer, esophageal cancer, lung cancer, thyroid cancer, breast cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer (NSCLC), ovarian cancer, soft-tissue sarcoma, or pancreatic cancer. [0824] Exemplary Embodiment 34. The method of Exemplary Embodiment 33, wherein the cancer is pancreatic cancer. [0825] Exemplary Embodiment 35. The method of Exemplary Embodiment 33, wherein the cancer is ovarian cancer. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0826] Exemplary Embodiment 36. The method of Exemplary Embodiment 35, wherein the ovarian cancer is platinum-resistant ovarian cancer. [0827] Exemplary Embodiment 37. The method of Exemplary Embodiment 35, wherein the ovarian cancer is platinum-resistant advanced ovarian cancer. [0828] Exemplary Embodiment 38. The method of Exemplary Embodiment 35, wherein the ovarian cancer is platinum refractory ovarian cancer. [0829] Exemplary Embodiment 39. A method of treating solid tumor in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of Compound A: (Compound A), and an effective amount of a second therapeutic agent selected from capecitabine, gemcitabine, metformin, IACS-010759 and fluorouracil (5-FU). EXAMPLES [0830] The following examples provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention and is not intended to limit the scope of what the inventors regard as their invention nor is it intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be assumed. Standard abbreviations may be used. Example 1. Phase 1 Results of Compound A in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Study Objectives [0831] Primary objectives of the study were to determine the recommended Phase 2 dose (RP2D) and maximum-tolerated dose (MTD) of Compound A in combination with capecitabine and gemcitabine in solid tumors. The secondary objectives of the study were (a) to evaluate the safety and tolerability, (b) to determine the pharmacokinetic parameters and optimal dosing regimen for each combination, and (c) to characterize the preliminary anti- tumor activity for each combination. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 Methods – Study Design [0832] Key Inclusion Criteria • ECOG performance status of 0-1 • Measurable disease defined by disease-specific criteria • Advanced solid tumors: breast, recurrent squamous cell carcinoma of the head and neck (HNSCC), ovarian, soft-tissue sarcoma, and pancreatic cancer [0833] Key Exclusion Criteria Compound A/Capecitabine • Absolute neutrophil count < 1.0 × 10 ⁹ /L • Platelets < 75 × 10 ⁹ /L • Hemoglobin < 9.0 g/dL • Creatinine Clearance < 50 mL/min (capecitabine) • AST/ALT > 2.0 x ULN Compound A/Gemcitabine • Absolute neutrophil count < 1.5 × 10 ⁹ /L • Platelets < 100 × 10 ⁹ /L • Hemoglobin < 9.0 g/dL • Creatinine Clearance < 40 mL/min • AST/ALT > 2.0 x ULN [0834] The study design is summarized in Table 1. Table 1. Summary of the Study Design [0835] Dose-escalation proceeded 3+3 design. Starting Dose was 100 mg QD with capecitabine or gemcitabine. Up to 9 patients were allowed to be backfilled into the highest cleared dose level. Treatment was administered until disease progression, unacceptable toxicity, or withdrawal. Response assessments were done every 2 cycles (6 weeks – capecitabine or 8 weeks – gemcitabine) by RECIST v1.1. Results [0836] 35 patients were enrolled in Phase 1 combination cohorts, 22 in combination with capecitabine and 13 in combination with gemcitabine. A summary of the demographics and 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 characteristics is presented in Table 2. An overview of the patient enrollment and disposition is provided in Table 3 and FIG.1. Table 2. Patient Demographics and Characteristics Table 3. Enrollment by Compound A Dose Level Dose-Escalation and Determination of MTD [0837] Capecitabine: 0 patients experienced a dose-limiting-toxicity (DLT) at any dose level and 3 patients had treatment-emergent adverse events (TRAEs) requiring dose modification. [0838] Gemcitabine: Post-amendment where DLT redefined, 1 patient experienced a DLT at 300 mg Compound A and 8 patients had TRAEs requiring dose modification. [0839] An overview the capecitabine and gemcitabine DLTs and TRAEs that required Compound A dose modification is provided in Table 4. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 Table 4. Capecitabine/Gemcitabine DLTs and TRAEs Requiring Compound A Dose Modification Note: Cape/Gem stands for Capecitabine/Gemcitabine Safety [0840] A summary of treatment-emergent adverse events occurring in ^ 10 % of patients by relatedness is shown in FIGs.2A and 2B and Table 5. [0841] All TRAEs [0842] Capecitabine: 45.5% of patient reported any grade events and 9.1% reported Gr3/4 across all cohorts; [0843] Gemcitabine: 69.2% of patient reported any grade events and 46.2% reported Gr3/4 across all cohorts. [0844] Most common TRAEs [0845] Capecitabine: fatigue (27.3%), decreased appetite (13.6%), nausea (13.6); [0846] Gemcitabine: fatigue (38.5%), anemia (23.1%), neutropenia (23.1%). [0847] No treatment-related deaths have been reported. Table 5. Safety Overview by Combination Cohort and Dose Level 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 Pharmacokinetic Analysis [0848] Exposure of Compound A in combination, with capecitabine or gemcitabine, exhibited dose proportional behavior. Exposure of Compound A was similar between combination therapy with capecitabine or gemcitabine and monotherapy. Mean steady-state trough levels achieved for Compound A in combination therapy exceeded levels where preclinical studies demonstrated activity. Compound A pharmacokinetic profiles across combination dose levels are shown in FIGs.3A and 3B and a summary of Compound A pharmacokinetic parameters across combination dose levels is provided in Table 6. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 Table 6. Summary of Compound A Pharmacokinetic Parameters Across Combination Dose Levels Clinical Activity in Solid Tumors with Compound A and Capecitabine [0849] The plot of the duration of treatment and response using the combination of Compound A and capecitabine is provided in FIG.4 and the plot of best percentage change in tumor size is shown in FIG.5. • 14 patients response evaluable with RECIST measurements available • 1 confirmed partial response (PR) in a patient with ovarian cancer treated at 300mg for 11 cycles • 9 patients had stable disease (SD) • The overall disease control rate was 71.4% [0850] 67-year-old female (Patient 184) with high grade serous ovarian cancer previously treated with 11 lines of therapy, including carboplatin, paclitaxel, gemcitabine, bevacizumab, topotecan, Doxil, pembrolizumab, cyclophosphamide. Her most recent two therapies were nab-paclitaxel/bev and pemetrexed with best response of PD. She was treated with Compound A starting at 300 mg QD and experienced a PR after 7 cycles, confirmed at 9 cycles, shown here (study day 167), with – 35% reduction in the sum of target lesion longest diameters. She continued on treatment at Cycle 12. FIG.6 depicts PR in ovarian cancer with Compound A (300 mg) and Capecitabine. Clinical Activity in Solid Tumors with Compound A and Gemcitabine 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0851] The plot of the duration of treatment and response using the combination of Compound A and gemcitabine is provided in FIG.7 and the plot of best percentage change in tumor size is shown in FIG.8. • 8 patients with solid tumors were response evaluable • 1 confirmed PR in a patient with soft tissue sarcoma at month 2 • 6 patients with SD • Disease control rate 87.5% Conclusions [0852] Exposure of Compound A in combination with capecitabine or gemcitabine exhibited dose proportional behavior and was similar between combination therapy and monotherapy. 400 mg Compound A was selected as the RP2D in combination with capecitabine as no DLTs were observed at any dose and the MTD was not identified. Dose escalation of Compound A and gemcitabine cleared the 200 mg level. Both combinations demonstrated an acceptable safety and tolerability profile without any unanticipated toxicities at clinically active doses. Encouraging antitumor activity was observed with a confirmed PR in heavily pretreated patients with both combination regimens. In the Compound A/capecitabine combination, encouraging preliminary activity was observed in the six evaluable ovarian cancer patients, with one confirmed PR and four SDs. The 400 mg cohort is being expanded with additional patients with ovarian cancer. Example 2. Dose Expansion Results of Compound A in Combination with Capecitabine in Platinum-Resistant Ovarian Cancer [0853] In the phase 1 dose escalation trial of Compound A plus capecitabine, 400 mg was identified as the recommended phase 2 dose. In three phase 2 trials, capecitabine had a RECIST response rate of 5-8% in ovarian cancer. [0854] An expansion cohort of 10 patients with platinum resistant advanced ovarian cancer were treated with Compound A, 400 mg orally once daily in combination with capecitabine, 1000 mg/m ² PO BID x 14 days every 21 days and were evaluable. One additional patient treated at the 300 mg dose level was evaluable and added to the analysis. The primary objective was safety, and secondary objectives were pharmacokinetics and preliminary anti- tumor activity by RECIST. [0855] 11 patients were treated and evaluable with a median age of 64 (range 52-76). Median prior therapies were 6 (range 2-14). All but one had 3 or more prior therapies. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 Median Compound A dose compliance with continuous daily dosing was 99% (range 91– 100%). There were no treatment discontinuations or Compound A dose reductions for treatment related adverse events.7 patients (64%) experienced a treatment-related adverse event, all were Grade 1-2. There were no grade 3+ treatment related adverse events. The most common related adverse events (AEs) were fatigue reported in 5 patients (46%), and decreased appetite, diarrhea, nausea, palmar-plantar erythrodysaesthesia syndrome and vomiting, each reported in 2 patients (18%). Exposure of Compound A in combination with capecitabine exhibits dose proportional behavior and was similar between combination therapy and monotherapy. One patient had a confirmed PR with progression on day 294, and 2 additional patients achieved an unconfirmed PR, with treatment ongoing on day 113 and 41.7 patients had SD, and one patient PD as best response. The disease control rate was 91%. 5 patients discontinued for progressive disease with a median of 133 days of treatment (range 43-300), and 2 withdrew on days 131-133.4 patients continue therapy on days 42, 47, 106, and 113. Median PFS was 170 days (95% CI 79-NA). [0856] The oral outpatient combination of Compound A and capecitabine has demonstrated an acceptable safety and tolerability profile without any unanticipated toxicities at clinically active doses. The disease control rate is 91% and unconfirmed response rate is 27% in refractory platinum resistant ovarian cancer. Example 3. Compound A Induces Metabolic Rewiring [0857] Raji cells were treated with a titration of Compound A, metformin, or the combination of both drugs, cell viability was measured and data plotted using the NCI method (FIG.9). Metformin at concentrations known to inhibit oxidative phosphorylation (OXPHOS) had little effect on cell viability as a single agent, but when combined with Compound A profoundly enhanced cytotoxicity. Similar results were observed with other inhibitors of oxidative phosphorylation, such as IACS-010759. Example 4. Synthetic Lethality Identified with Compound A [0858] Several significant synthetic lethal hitswere identified in the Compound A sensitivity CRISPR screens. Briefly, the human pancreatic cancer cell line, SU8686, and the human breast cancer cell line, T47D, were utilized in a CRISPR screen to identify sensitizing factors to Compound A. T47D cells were moderately sensitive to Compound A treatment, with a GI50 of 2-3 uM in a viability assay, and SU8686 cells were much less sensitive with a GI50 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 of >5 uM in a viability assay. Both cell lines were transduced with an “all-in-one” whole genome lentiviral library containing viral particles enabling expression of both spCas9 and sgRNA’s targeting each gene in the genome. Cells were selected for successful integration of the viral material with puromycin, and then split into separate treatments of DMSO or a cell line-specific GI20 dose of Compound A. A third treatment group was utilized for the T47D cell line as well, and consisted of a GI80 dose of Compound A. Cells were passaged and expanded for at least 8 doublings of the DMSO control with an attempt at maintaining >300- fold library coverage. Following treatment, cells were harvested, genomic DNA was extracted and sequenced using the Illumina NextSeq platform, and abundance of sgRNA and screen hits were determined using the drugZ platform. A screen hit is defined as a gene that when genetically disrupted results in increased Compound A-mediated cell growth inhibition. The most statistically significant hit in the SU8686 screen was TYMS, the gene that encodes for the thymidylate synthetase protein, which is one of the molecular targets of 5-fluorouracil (FIG.10). When genes were sorted by drugZ score, TYMS was the 346 ^th highest scoring hit in the T47D screen performed in the presence of a GI20 dose of Compound A and was not considered statistically significant. However, TYMS was the 6 ^th highest scoring hit in the T47D screen performed in the presence of a GI80 dose of Compound A, and was one of few genes showing a dose-dependency. [0859] Gene set enrichment analysis of the CRISPR screen hits identified metabolism and metabolic pathways (FIG.11), suggesting genetic alterations or pharmacological inhibition of these pathways could represent viable biomarker or combination strategies. Example 5. In Vitro Combination of Compound A and 5-Fluorouracil Synergistically Inhibits Pancreatic Cancer Cell Line Growth [0860] The combination of 5-fluorouracil (5-FU) with Compound A was tested in vitro, resulting in synergistic cell growth inhibition in a subset of cell lines. A panel of human pancreatic cancer and other cancer subtype cell lines were tested for sensitivity to Compound A as a single agent and in combination with 5-fluorouracil (5-FU) or gemcitabine in a cell viability assay (FIGs.12 and 13). In brief, cell lines were plated in 96 well plates at their pre- determined optimal growth density for a 7-day viability assay. The following day, cells were exposed to either a titration of Compound A alone at a top concentration of 20 uM with a 5- point, 3-fold serial dilution, a titration of 5-FU alone at a top concentration of 20 uM with an 8-point, 3-fold serial dilution, a combinatorial matrix of each single agent concentration used 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 for each drug, or DMSO control. After 7-days relative cell viability was measured using the Promega Cell Titer-Glo 2.0 assay per manufacturer’s protocol and a plate reader capable of measuring luminescence. Cell growth inhibition and synergy metrics were calculated using a variety of standard techniques, including Chou-Talalay synergy, Bliss independence synergy, and GR metrics. The pancreatic cancer cell line PANC0403 was relatively insensitive to either single agent treatment. However, drug treatment with the combination of Compound A and 5-FU resulted in synergistic cell growth inhibition across a range of the combinatorial matrix, with a Chou-Talalay combination index score between 0.23 and 0.65 (values below 1 are considered synergistic) and a Bliss independence synergy score of between 3.3 and 5.3 (values greater than 3 are generally considered to be synergistic) (FIGs.14A-14D). Other cancer cell lines tested showed an additive cell growth inhibition effect when treated with Compound A and 5-FU. Example 6. In Vivo Combination [0861] Immunocompromised balb/c nude mice were xenografted with the MiaPaca-2 human pancreatic cancer cell line. Once tumors were palpable and reached a pre-specified cohort median tumor volume of 150 cubic mm, mice were randomized into treatment groups and drug treatment initiated. Treatment groups were vehicle control, Compound A initially dosed once daily at 200 mg/kg orally, capecitabine dosed once daily at 400 mg/kg orally on a 14 day on/7 day off schedule, or the combination of both oral drug treatments. Drug holidays were given to individual animals that experienced body weight loss of greater than 15% relative to the first day of treatment, and treatment was re-initiated once that animal’s body weight loss returned to less than 10% relative to the first day of treatment. Compound A treatment in both the single agent and combination arms were reduced to 120 mg/kg once daily due to observed clinical signs that had not previously been seen in this mouse strain, and thus was possibly specific to the cancer cell model. The final tumor measurements were taken 35 days post initiation of treatment, tumor growth inhibition (TGI) was calculated using the relative tumor volume method, and a 2-way ANOVA analysis with post-hoc Tukey multiple comparison tests were performed. Neither Compound A nor capecitabine single agent treatment arms achieved statistically significant TGI relative to vehicle-treated control mice, displaying -16.3% and -6.7% TGI, respectively. However, treatment with both drugs in combination achieved a synergistic 53.7% TGI compared to vehicle control-treated mice, achieving statistical significance with a p-value < 0.001 (FIGs.15 and 16). 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 Example 7. Phase 1 Dose Expansion Results of Compound A in Combination with Capecitabine in Platinum-Resistant Ovarian Cancer [0862] The study provided the results of an expansion cohort of 10 evaluable patients with platinum-resistant advanced ovarian cancer that were treated with Compound A, 400 mg QD in combination with capecitabine, 1000 mg/m ² PO BID x 14 days every 21 days. One additional patient treated at the 300 mg dose level was evaluable and added to the analysis. [0863] Study Objectives [0864] The primary objective of this study was to evaluate the safety and tolerability. The secondary objectives were to determine the pharmacokinetic parameters and optimal dosing regimen for the combination and to characterize the preliminary anti-tumor activity for the combination. [0865] Methods – Study Design Eligibility Criteria [0866] Key Inclusion Criteria: (a) ECOG 0-1 (b) Measurable disease by disease-specific criteria (c) Advanced solid tumors (i) Breast, HNSCC, ovarian, soft-tissue sarcoma, and pancreatic cancer (ii)Expansion: Platinum resistant ovarian cancer only [0867] Key Exclusion Criteria Compound A/Capecitabine - Absolute neutrophil count < 1.0 × 10 ⁹ /L - Platelets < 75 × 10 ⁹ /L - Hemoglobin < 9.0 g/dL - Creatinine clearance < 50 mL/min (capecitabine) - AST/ALT > 2.0 x ULN [0868] Phase 1 Combination Study Design [0869] The study design is provided in Table 7. Table 7. Study Design 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 [0870] Results [0871] Demographics and Disposition [0872] 14 Patients with ovarian cancer were enrolled in the Compound A + capecitabine combination cohorts, 11 were evaluable for response, 3 (27%) remain on treatment. Demographics and patient characteristics is provided in Table 8. Table 8. Demographics and Patient Characteristics [0873] Safety [0874] All TEAEs- 91% of patients reported any grade events, and 73% reported a treatment related adverse event.18% reported a grade 3/4 adverse event, and no patient reported any treatment related grade 3/4 adverse event. There were no grade 5 adverse events. There were no treatment related adverse events leading to Compound A dose reduction or discontinuation. Most common TRAEs were fatigue (46%), palmar-plantar erythrodysaesthesia syndrome (18%), vomiting (18%), decreased appetite (18%), diarrhoea 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 (18%), and nausea (18%), all grade 1 or 2. The treatment-emergent adverse events occurring in ^ 10 % of patients by relatedness are depicted in FIG.17. [0875] Treatment Compliance [0876] Median Compound A dose compliance with continuous daily dosing was 99% (range 94 – 100%). There were no treatment discontinuations or Compound A dose reductions for treatment related adverse events. [0877] Pharmacokinetic Analysis [0878] Exposure of Compound A in combination with capecitabine exhibits dose proportional behavior and was similar between combination therapy and monotherapy. Mean steady-state trough levels achieved for Compound A in combination therapy exceed levels where preclinical studies demonstrated activity. Compound A pharmacokinetic profiles across combination dose levels is provided in FIG.18 and Table 9. Table 9: Summary of Compound A Pharmacokinetic Parameters Across Combination Dose Levels ^a : median (min, max) ^b : geometric mean ± standard deviation [0879] Clinical Activity in Ovarian Cancer with Compound A + Capecitabine [0880] FIGs.19-24 depict clinical activity in ovarian cancer with Compound A and capecitabine. [0881] Conclusions [0882] The combination of Compound A and capecitabine demonstrated an acceptable safety and tolerability profile without any unanticipated toxicities at clinically active doses. The combination of Compound A and capecitabine is an oral outpatient regimen that 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 appeared active in heavily pretreated platinum refractory and platinum resistant ovarian cancer. The disease control rate of 91% and unconfirmed response rate of 27% in platinum refractory and platinum resistant ovarian cancer is promising. Furthermore, this regimen should be evaluated in other tumor types commonly treated with 5-FU, including breast and colorectal cancer. 292800319 v3 Docket No. CYTH-023/001WO 335739-2181 EQUIVALENTS [0883] The details of one or more embodiments of the disclosure are set forth in the accompanying description above. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated by reference. [0884] The foregoing description has been presented only for the purposes of illustration and is not intended to limit the disclosure to the precise form disclosed, but by the claims appended hereto. 292800319 v3